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ABSTRACT 
 
Objectives – To measure the effect of non – asthmatic atopy (NAA) on the risk of adverse pregnancy 
outcomes; low birth weight (LBW), small for gestational age (SGA) and preterm birth (PTB), among 
primiparous women 19 – 25 years of age. 
 
Methods – Vital Statistics records from births occurring between 2004 and 2014, from approximately 
60,000 primiparous women in South Carolina, aged 19 to 25 years, were linked to their Medicaid 
records. Maternal records were examined to determine if they had a previous diagnosis of NAA. Women 
with a diagnosis of NAA were frequency matched with a ratio of 1:4 to non – atopic controls by age, sex 
of infant, and asthma diagnosis. Next, the frequencies of LBW, SGA and PTB were compared across the 
two groups of women. Tests for linear trend across birth weight categories and gestational age at birth 
categories were then conducted after which separate Poisson regression models were estimated to 
measure the risk of each outcome. 
 
Results – Linear tests for increasing trend were statistically significant (p < 0.001); indicating that higher 
percentages of NAA are associated with higher infant birth weight. Similarly, higher percentages of NAA 
were associated with greater gestational age at birth. After controlling for maternal race/ethnicity, 
smoking during pregnancy, gestational diabetes and pre – pregnancy hypertension; mothers with a 
diagnosis of NAA had reduced risk for each outcome (RR = 0.96, 0.94 and 0.95 for LBW, SGA and 
 x 
 
PTB respectively). These results were not statistically significant (p > 0.05). Similar results were seen when 
data was further explored by maternal race/ethnicity. 
 
Conclusions – NAA could promote a healthy pregnancy and reduce the risk of adverse outcomes and 
should therefore be taken into account when assessing a woman’s risk of same. Until now this protection 
has gone unnoticed due to the increase in the risk of study outcomes that are associated with a diagnosis 
of asthma, and the fact that in many instances asthma is present with NAA. Additional analyses are 
needed to evaluate unknown factors associated with its diagnosis and treatment. 
 
 
   
 
 
1 
 
 
 
 
CHAPTER ONE: INTRODUCTION 
 
There is an increasing trend of allergic sensitization among children and young adults which 
has been documented since the 1990s (Deckers et al., 2012). This sensitization is responsible for 
disorders such as allergic rhinitis, atopic dermatitis as well as eczema (Deckers et al., 2012; Ruby 
Pawankar, Canonica, Holgate, & Lockey, 2012). Atopic disorders are the most common chronic 
diseases in the developed world (Ruby Pawankar et al., 2012). The prevalence of atopic dermatitis 
(AD) has doubled or tripled in industrialized countries over the last three decades (Bieber, 2008; 
Simpson et al., 2001). Allergic rhinitis (AR) affects between 10% to 30% of the world’s population 
(AAAAI, 2015; Ruby  Pawankar, Walter Canonica, Holgate, & Lockey, 2011). With increasing 
trends comes the need to better understand how allergic sensitization and suffering from chronic 
allergies affect the human body. One very visible effect of this worsening phenomenon is the 
increased burden that it places on the health care sector in the form of doctor visits and prescription 
costs (Franzese, 2011). There is also an impact on the economy due to loss of productivity from 
absenteeism, time spent away from work, and/or those same doctor visits (Franzese, 2011). 
Productivity losses that are due to presenteeism can also be seen, where employees are on the job 
but underperform due to experiencing allergic symptoms (Lamb et al., 2006; Zuberbier, Lötvall, 
Simoens, Subramanian, & Church, 2014) 
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Another visible effect of this worsening phenomenon is how atopic symptoms, namely 
asthma during pregnancy affects birth outcomes. Researchers have found that uncontrolled asthma 
during pregnancy can lead to adverse pregnancy outcomes such as low birth weight (LBW) and 
preterm birth (PTB) (Firoozi et al., 2010; V. Murphy et al., 2011; Trønnes et al., 2014). There are 
few studies that have addressed the effect of other atopic disorders, non – asthmatic atopy (NAA); 
allergic rhinitis and atopic dermatitis, have on a developing fetus and the final outcome of 
pregnancy. 
The increasing prevalence of these conditions make it important to address the question of 
their effect on pregnancy as a woman’s risk of adverse outcomes may be influenced by a diagnosis of 
non – asthmatic atopy.  
 
1.1 STATEMENT OF THE PROBLEM 
Atopic disorders are the most common chronic diseases in the developed world (Ruby 
Pawankar et al., 2012). The prevalence of atopic dermatitis has doubled or tripled in industrialized 
countries over the past three decades (Bieber, 2008; Simpson et al., 2001). Allergic Rhinitis affects 
up to one – third of the world’s population (Ruby  Pawankar et al., 2011). There is a gap in the 
current literature on how non – asthmatic atopy affects pregnancy outcomes. Therefore this study 
examined the association between maternal atopic disorders and pregnancy outcomes.  
 
Research Question 1 
Does non – asthmatic atopy in women adversely affect pregnancy outcomes? 
 
 3 
 
 
Hypothesis 1 
 There are differences in the risk of adverse pregnancy outcomes between primiparous women 
who have non – asthmatic atopy and those who don’t. 
 
Research Question 2  
Does maternal race/ethnicity modify the effect of non – asthmatic atopy on pregnancy 
outcomes?  
 
Hypothesis 2 
 There are differences in the way that maternal race/ethnicity affects pregnancy outcomes 
between primiparous women with non – asthmatic atopy and those without. 
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CHAPTER TWO: REVIEW OF THE LITERATURE 
 
2.1 PREGNANCY 
During the first trimester of pregnancy, the fetus neural tube (brain and spinal cord) is well 
formed. Other systems such as the digestive tract and sensory organs begin to develop during this 
time, and bone begins to replace cartilage. Towards the end of the first trimester, the fetus circulatory 
and urinary systems are functional. The most critical development of the fetus takes place during 
the first trimester and the chance of miscarriage is greatly reduced after 13 weeks of pregnancy. 
Due to a number of reasons, some mothers may experience adverse outcomes at the end of 
their pregnancy. Adverse outcomes include having an infant born with low birth weight (LBW), 
(weighing less than 2500 grams or 5.5 pounds at birth), very low birth weight (weighing less than 
1500 grams or 3.33 pounds at birth) being born pre – term, Preterm Birth (PTB),  (less than 37 
weeks gestation), very pre – term (less than 32 weeks of gestation) or being born with a birth defect 
as well as stillbirth (CDC, 2014a, 2014b). Another adverse pregnancy outcome is intra – uterine 
growth restriction or being born small for gestational age (SGA) (Clayton et al., 2007). It is known 
that birth weight is positively correlated to gestational age. The SGA statistic takes into account 
gestational age at birth when measuring birth weight of a newborn. A newborn with a birth weight 
less than the 10th percentile for their gestational age and gender is considered to be SGA (CDC, 
2014b). Because birth weights are very population specific, other researchers have classified infants 
as being SGA if they have a birth weight less than 2 standard deviations from the sex – and 
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gestational age – specific mean, of their study sample (Trønnes et al., 2014). These outcomes; low 
birth weight, small for gestational age, and preterm birth are associated with further issues during 
childhood and survival into adulthood. Other health indicators of fetal wellbeing at birth include 
Apgar score (Apgar, 1952). The Apgar score ranges between 0 and 10 with scores below 7 indicating 
an adverse pregnancy outcome. Issues such as survival, developmental delays, failure to thrive, as 
well as severe disability are more prevalent among this population of babies (Anderson et al., 2011; 
Kelleher et al., 1993; Kotecha et al., 2012; Lindström, Lindblad, & Hjern, 2011).  
Several risk factors for adverse pregnancy outcomes have been identified. Risk factors 
including maternal characteristics such as: chronic diseases; e.g. hypertension (Lindheimer, 1993) 
and diabetes (Arulkumaran, 2011). It is well documented that hypertension during pregnancy has 
the potential to escalate causing pre – eclampsia leading to intra – uterine growth restriction and 
preterm birth (Lindheimer, 1993; Vest & Cho, 2012). Pre – existing Type I and Type II diabetes as 
well as gestational diabetes increase the risk of intra – uterine growth restriction which leads to low 
birth weight, macrosomia and stillbirth (Casson et al., 1997; Yogev & Visser, 2009). These 
conditions are also risk factors for poor health outcomes in the mother (Arulkumaran, 2011). 
Uncomplicated obesity in the mother still puts her at risk for macrosomia in her offspring as well as 
increasing her risks of developing hypertension and diabetes (Yogev & Visser, 2009). It is also well 
documented that smoking during pregnancy increases the risk of adverse outcomes for the fetus 
such as, low birth weight, small for gestational age as well as preterm birth (Ko et al., 2014; 
SILVERMAN, 1977). Other maternal characteristics that influence pregnancy outcomes include 
maternal age and number of previous pregnancies. Expectant mothers considered to be at higher 
risk may be more closely monitored to better ensure the best possible outcome. In such cases 
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increased monitoring and access to early intervention may be the best assets to ensure the best 
possible outcome for both the mother and the child. 
Adverse pregnancy outcomes such as low birth weight (Fuentes-Afflick & Lurie, 1997; James, 
1993) and preterm birth (CDC, 2013b) are disproportionately distributed across race/ethnicity. The 
2013 prevalence of low birth weight was 7.0%, 13.1% & 7.1% for white, black and Hispanic women 
respectively (CDC, 2014b). The 2013 prevalence of preterm birth was 10.8%, 17.1% and 11.8% for 
white, black and Hispanic women respectively (CDC, 2013b). After controlling for obesity, 
hypertension, diabetes and prenatal care, black women (adjusted OR = 2.5) and Hispanic women 
(adjusted OR = 1.4) had an increased risk for delivering an infant prematurely when compared to 
white women (Johnson, Rottier, Luellwitz, & Kirby, 2009). 
 
2.2 ATOPY 
Atopy can be defined as the genetic tendency to develop allergic disorders such as asthma, 
allergic rhinitis (AR) and atopic dermatitis (AD) (AAAAI, 2015). Allergic rhinitis, more commonly 
referred to as hay fever and atopic dermatitis, more commonly referred to as eczema, are also 
generally referred to as allergies. The rates of these disorders are increasing worldwide (Ruby 
Pawankar et al., 2012). In the United States there are approximately 17.2 million (8.7%) adults and 
4.6 million (6.5%) children with asthma (CDC, 2013a). The prevalence of asthma is higher among 
women (10.7%) when compared to men (6.5%) (CDC, 2013a).  
Asthma is a chronic disorder that affects the airways and is associated with atopy. These 
airways are inflamed in people with asthma and they are sensitive to triggers (AAAAI, 2015). When 
exposed to a trigger, the increased sensitivity leads to an immune response which is at first dominated 
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by T – helper 1 cells (associated with airway inflammation) and later on is dominated by T – helper 
2 cells (associated with mucus production) (Bergqvist et al., 2015). During asthmatic symptom flare 
ups, a person usually finds it difficult to breathe. Asthma can be an indicator of the presence of 
other atopic disorders such as allergic rhinitis (AR) and atopic dermatitis (AD). Between 30% and 
80% of asthma patients also reported having AR (Kim, Bouchard, & Renzix, 2008) while 40% of 
patients with AR also reported having asthma (Kim et al., 2008). However, even with suspected 
under diagnosis of atopy (Greiner, Hellings, Rotiroti, & Scadding, 2012), persons may have only 
one atopic disorder and may never develop or display any symptoms of the others. 
Allergic rhinitis (AR) is a disorder of the nose characterized by a T – helper 2 cell dominated 
immune response after exposure to an allergen (Bousquet et al., 2012; Feng, Miller, & Simon, 2012; 
Rondón et al., 2012). This response usually produces symptoms such as sneezing, nasal congestion 
and runny nose (Bousquet et al., 2012; Skoner, 2001). Allergens such as dust, mold and mites can 
trigger symptoms which is largely an overreaction to the irritant. Allergic rhinitis is not a serious 
disorder and anti – histamine as well as intranasal corticosteroids have been used to treat the 
symptoms (Greiner et al., 2012). It has been postulated that while not a serious disease on its own, 
AR can put a person at risk for developing asthma, or, symptom flare ups of previously diagnosed 
asthma (Bousquet et al., 2012; Greiner et al., 2012). The presence of AR can be confirmed with a 
skin prick test (SPT) (Feng et al., 2012; Rondón et al., 2012). 
Atopic Dermatitis (AD) is a chronic or recurrent inflammatory skin disease (AAAAI, 2015; 
Akdis et al., 2006). It has a complex pathogenesis which includes skin barrier dysfunction and 
allergy/immunological responses (Kabashima, 2013). AD symptoms usually flare up due to T – 
helper 2 mediated immune responses to different triggers (Hijnen et al., 2013). In chronic cases a 
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person’s skin does not appear normal due to tissue remodeling caused by severe inflammation (Akdis 
et al., 2006). 
Atopic disorders are the most common chronic diseases present in the developed world 
(Simpson et al., 2001). While their precise mechanism is not fully understand there are many factors 
that contribute to the development and manifestation of atopic symptoms. There are still questions 
as to whether the likelihood of developing atopy increases or decreases with increased sibship 
(Karmaus & Botezan, 2002; Rona, Duran-Tauleria, & Chinn, 1997).  There has also been ethnic 
differences noted in the prevalence and type of atopic symptoms observed with allergic rhinitis and 
other allergies affecting the airways more prevalent in European and Australian countries (Hjern, 
Haglund, & Hedlin, 2000), and atopic dermatitis being more prevalent in African countries 
(Williams et al., 1999). 
In the United States approximately 20 – 25% of the general adult population, between the 
ages of 16 – 65, is affected by an allergic disorder (Franzese, 2011; Sibbald & Rink, 1991). While 
there is increasing knowledge about these disorders, the circumstances leading to the development 
or exacerbation of atopy are not fully understood. Researchers have identified many environmental 
risk factors that can lead to the worsening of allergic symptoms experienced in the population. Air 
quality has been identified as an important environmental risk factor in modifying symptoms of 
allergies. When air quality is low and there is exposure to air pollutants, allergic symptoms and other 
manifestations of allergies can be exacerbated (Strachan, Wong, & Spector, 2001; Wyler et al., 
2000). Allergens and irritants that are present in personal environments (e.g. home) such as 
fragrances, pet and animal dander can worsen allergic symptoms (Simpson et al., 2001). Typically, 
the symptoms associated with allergic sensitization are worse during childhood as the immune 
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system has an immature response to allergens. The National Center for Health Statistics (NCHS) 
data brief; Trends in Allergic Conditions among Children: United States 1997 – 2011 (Jackson, 
Howie, & Akinbami, 2013), states that the prevalence of respiratory related allergies in children is 
approximately 17% which represents an increasing trend over previous decades (Jackson et al., 
2013).  In the past, allergic symptoms decreased as children got older which led to a smaller 
prevalence of allergies among adults. Trends found among young adults could be due to the type of 
allergy symptom being examined. Younger children are more likely to have skin allergies, while older 
children and young adults are more likely to have respiratory allergies (Jackson et al., 2013). An 
argument could therefore be made that the prevalence of respiratory allergies increases with age 
which would explain the higher rates being exhibited in adults. In addition to this, there are 
increasing trends in the prevalence of respiratory allergies worldwide (Dotterud & Smith‐Sivertsen, 
2007).  Furthermore, many adults have reported that they became sensitized for the first time in 
adulthood (Schäfer et al., 2001). 
Doctors and other health care providers are faced with the challenge of prescribing 
medications that will relieve symptoms and which cause few side effects even when taken for a 
relatively long period of time. Prescription therapy for treating atopic dermatitis and eczema are 
varied in the literature (Akdis et al., 2006; Hanifin, Ling, Langley, Breneman, & Rafal, 2001). 
Treatment for atopic dermatitis should comprise of optimal skin care, promoting skin repair and 
hydration, along with avoidance of known triggers (Akdis et al., 2006). Treatment is also largely 
dependent on the severity of symptoms (Greiner et al., 2012). Treatment for allergic rhinitis is 
similarly varied. It ranges from simple nasal treatments such as saline nasal irrigation 
(Hermelingmeier, Weber, Hellmich, Heubach, & Mösges, 2012) to intra – nasal corticosteroids 
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(Greiner et al., 2012). Patient perception of the side effects of particular medication can also 
influence the outcome of treatment and even with the best treatment options one in five patients 
remain highly symptomatic (Greiner et al., 2012). In addition, patients may not always comply with 
treatment medication as they fear adverse events associated with the medications prescribed 
(Hellings et al., 2012). 
 
2.3 ATOPY DURING PREGNANCY 
 
2.3.1 ASTHMA 
Asthma is the most common chronic disease that affects women during pregnancy (Maselli, 
Adams, Peters, & Levine, 2013) and it can have a significant impact on the outcome of the pregnancy 
(Aly et al., 2011; V. Murphy et al., 2011). During pregnancy, changes occur in a woman’s pulmonary 
physiology such as, minute ventilation (the amount of air entering the lungs each minute) increasing 
due to the higher levels of progesterone which are present in her body (Maselli et al., 2013).   
In their review article and subsequent meta – analysis, Murphy et al found that maternal 
asthma was associated with adverse pregnancy outcomes affecting the newborn such as low birth 
weight (LBW) and preterm birth (PTB) (V. Murphy et al., 2011). They found that asthma in mothers 
led to a 46% increase in the risk of low birth weight, a 22% increase in the risk of the infant being 
born small for gestational age (SGA) and a 41% increase in the risk of preterm birth (V. Murphy et 
al., 2011). Asthma  during pregnancy also led to adverse maternal outcomes such as complicated 
labor and pregnancy induced hypertension (V. Murphy et al., 2011). Firoozi et al also found similar 
results in that maternal asthma was associated with an increase in the odds of SGA and PTB (Firoozi 
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et al., 2010). The mechanism on how asthma could cause these adverse outcomes is not fully 
understood. However, due to the sequelae associated with asthmatic symptom flare ups, it has been 
postulated that maternal hypoxemia as well as the changing functions carried out by the placenta, 
led to the adverse maternal and fetal outcomes among asthmatic women during pregnancy (V. E. 
Murphy, Clifton, & Gibson, 2006). The effect of demographic factors such as Socioeconomic status 
(SES) is also not clearly understood (Firoozi et al., 2010). Bakhireva et al found that poorly controlled 
asthma in pregnant women puts them at an increased risk for preterm delivery and suggests that 
adequate treatment protocols and access to health care are necessary to maintain optimal asthma 
control and lessen adverse outcomes (Bakhireva, Schatz, Jones, & Chambers, 2008). 
Asthma surveillance data indicates that the prevalence of asthma is disproportionately 
distributed by race/ethnicity with 9.9% of African Americans/Blacks reporting a diagnosis of 
asthma while 7.6% of Whites and 6.7% of Hispanics reporting a diagnosis of asthma (CDC, 2013a). 
Murphy et al in their meta – analysis noted that due to regional differences observed, ethnic 
disparities are plausible (V. Murphy et al., 2011). While Aly et al in their 2011 study found that 
maternal asthma was associated with low birth weight outcomes in black non – Hispanic women 
(BNH) but not white non – Hispanic women (WNH) (Aly et al., 2011). They found that BNH 
women with asthma had a significant increase in the odds (OR = 1.7; p < 0.05) of low birth weight 
compared to BNH without asthma. While there was no statistically significant difference in the odds 
of low birth weight among WNH women with asthma compared to WNH women without asthma 
(OR = 0.99; p > 0.05) (Aly et al., 2011). However, Aly and colleagues did not account for the severity 
of asthma nor did they account for medication used for asthma control.  
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There is conflicting evidence about using medication to control asthma during pregnancy. 
Hodyl et al found that using Inhaled Corticosteroids (ICS) significantly impacted maternal 
glucocorticoid – regulated systems and not fetal system and furthermore, this impact was only 
demonstrated when pregnant with a female (Hodyl et al., 2011). They also found that fetal 
adrenaline functions were not significantly affected by maternal ICS use (Hodyl et al., 2011) and as 
such would not affect fetal growth and development. While this study suggests that ICS use poses 
minimal harm to fetal development, it does indicate that ICS use does have some effect on the 
woman. Nonetheless, Lim et al (Lim, Stewart, Abramson, & George, 2011) found that health care 
providers were hesitant to prescribe ICS to patients with asthma during pregnancy and McCusker 
et al (McCusker & Hamid, 2011) concluded that ICS use during pregnancy continued to be a 
concern for potential adverse outcomes for the pregnant woman and the developing fetus. This 
suggests that more research needs to be conducted to determine the best standard of care and 
treatment practice for women with asthma during pregnancy.   
 
2.3.2 ALLERGIC RHINITIS (AR) AND ATOPIC DERMATITIS (AD) 
 The effect of these maternal atopic disorders on pregnancy outcomes is not completely 
known or understood. Studies conducted so far, that have investigated the effect of these atopic 
disorders have found them to be significantly associated with a reduction in adverse pregnancy 
outcomes. Savilhati et al. found that the odds of mothers being diagnosed with Allergic Rhinitis 
(AR) was reduced by 50% (OR = 0.49; 95% CI 0.26 – 0.89) among infants born extremely low birth 
weight (less than 1000 g) and the odds of being diagnosed with Atopic Dermatitis (AD) was reduced 
by 36% (OR = 0.64; 95% CI 0.36 – 1.15) among ELBW (Savilahti, Siltanen, Pekkanen, & Kajosaari, 
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2004). Another study found that AR in mothers was associated with a reduced risk of congenital 
abnormalities (CA) by 30% (prevalence OR = 0.7; 95% CI 0.6 – 0.9) (Somoskövi et al., 2007).  
A recent study by Trønnes et al conducted on a Norwegian cohort found that maternal non 
– asthmatic atopy is associated with a protective effect for preterm birth, still birth and neonatal 
death and further that maternal asthma was associated with an increased risk of preterm birth 
(Trønnes et al., 2014). Asthma diagnosed in mothers increased the odds of preterm birth 15%, while 
AD and AR in mothers reduced the risk of same by 10% and 16% respectively (Trønnes et al., 2014). 
Atopy in pregnant women can also affect the overall development of the child. Croen et al, 
found that children whose mothers experienced atopy; including allergic rhinitis and atopic 
dermatitis were at an increased risk for being diagnosed with Autism Spectrum Disorders (ASD) 
(Croen, Grether, Yoshida, Odouli, & Van de Water, 2005). They further found evidence indicating 
that the timing of exposure modified this risk. They found that children whose mothers had any 
history of atopy had an increased risk of ASD and further that those whose mothers experienced 
atopic exacerbation during their second trimester of pregnancy were at a greater than 2 fold increased 
risk for developing ASD (Croen et al., 2005). 
Maternal atopy has been found to be associated with various outcomes in child development. 
It has been linked to the child’s immune responses stimuli (Amoudruz et al., 2005) and it has also 
been identified as a risk factor for the development of atopy in their offspring (Krauss-Etschmann et 
al., 2006; Pali-Schöll, Renz, & Jensen-Jarolim, 2009; Reece et al., 2011).  
Studies on the effect of maternal atopy on fetal and child development up to this point have 
mainly focused on allergic sensitization in the child (Krauss-Etschmann et al., 2006; Pali-Schöll et 
al., 2009; Reece et al., 2011). Few have explored other adverse outcomes manifesting later on in life 
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such as ASD (Croen et al., 2005). Fewer have been conducted in the United States exploring the 
effect of non – asthmatic atopy on adverse pregnancy outcomes. 
 
2.4 REVIEW OF METHODS USED IN THE LITERATURE 
 To characterize the effect of various atopic disorders including asthma, allergic rhinitis and 
atopic dermatitis, on pregnancy outcomes, standard statistical analytic methods have been employed, 
while researchers have utilized administrative databases to identify their study population. These 
studies have also used samples of varying size from 207 (Hodyl et al., 2011) to approximately 
2,000,000 (Trønnes et al., 2014). 
 
2.4.1 DATA SOURCES 
 Researchers have utilized various data sources such as linking information found in National 
Registries from over many decades (Trønnes et al., 2014) or linking information found in regional 
administrative databases for national health insurance programs (Firoozi et al., 2010). Aly et al were 
able to sample from a perinatal database of women delivering at a Medical Center  (Aly et al., 2011). 
While, Hodyl et al prospectively recruited 207 pregnant women at their first visit to an antenatal 
clinic (Hodyl et al., 2011). 
 
2.4.2 DEFINITION AND MEASUREMENT OF EXPOSURE 
In their study Trønnes et al identified allergic rhinoconjunctivitis using International 
Classification of Diseases ICD – 10 codes J30.1 – J30.4 and H10.1 and ICD – 8 code 507 (Trønnes 
et al., 2014). Atopic dermatitis was identified using ICD – 10 code L20 or where used ICD – 8 codes 
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691 and 692 (Trønnes et al., 2014). Asthma was identified using ICD – 10 code J45, ICD – 8 codes 
491 and 493) (Trønnes et al., 2014) and ICD – 9 code 493 (Firoozi et al., 2010). Other studies 
interviewed patients and classified them as having atopy based on self – reported history or 
documented history of same (Savilahti et al., 2004), while others only included patients who 
experienced exacerbations during pregnancy (Aly et al., 2011; Somoskövi et al., 2007). Hodyl et al 
used a diagnosis of asthma as documented by a physician (Hodyl et al., 2011). Asthma medication 
was indicated dichotomously as yes or no depending on whether or not there was a prescription by 
a physician on the patient’s chart (Hodyl et al., 2011).  
 
2.4.3 DEFINITION AND MEASUREMENT OF OUTCOMES 
Outcomes that have been examined include: preterm birth; still birth; and, neonatal death. 
Studies for the most part have used the global definitions of these routinely measured outcomes. A 
preterm birth was generally defined as a birth that occurred before completing the 37th week of 
gestation (Aly et al., 2011; Firoozi et al., 2010; Trønnes et al., 2014) . Small for gestational age (SGA) 
was defined as having a birth weight below 2 standard deviations from the mean of the sample 
according to gestational age and sex (Trønnes et al., 2014) or as a birth weight below the 10th 
percentile for gestational age and gender (Aly et al., 2011; Firoozi et al., 2010; Hodyl et al., 2011). A 
neonatal death was defined as death occurring within 28 days after a live birth (Trønnes et al., 2014). 
Blood samples were taken to measure clinical indicators of fetal and maternal functions when the 
mother took medication to treat her asthma symptoms while pregnant. (Hodyl et al., 2011). 
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2.4.4 STATISTICAL ANALYSIS 
Data analysis has employed the use of chi – square tests for bivariate associations (Aly et al., 
2011; Firoozi et al., 2010; Hodyl et al., 2011; Trønnes et al., 2014). Multivariable analyses used to 
quantify effects while controlling for other factors, included repeated measures log – binomial 
regression models (Trønnes et al., 2014) and logistic regression models (Aly et al., 2011; Firoozi et 
al., 2010). Hodyl et al performed log transformations, and employed the use of repeated measures 
ANOVA on the transformed birth weight data to describe the effect of medication on pregnancy 
outcomes (Hodyl et al., 2011).  
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CHAPTER THREE: METHODOLOGY 
 
 
3.1 STATEMENT OF RESEARCH QUESTIONS 
 
3.1.1 NON – ASTHMATIC ATOPY (NAA) AND PREGNANCY OUTCOMES  
This study seeks to determine if there exists an association between a diagnosis of maternal 
non – asthmatic atopy (NAA); allergic rhinitis (AR) and atopic dermatitis (AD), and adverse 
pregnancy outcomes; low birth weight (LBW), small for gestational age (SGA) and preterm birth 
(PTB). 
 
Research Question 1  
Does maternal NAA adversely affect pregnancy outcomes? 
 
Example of models to be fit: 
i) Among entire study sample 
Preterm Birth (Yes/No) ~ Maternal NAA – AR (Yes/No) | other predicting factors 
 
ii) Among infants born after completing 37 weeks of gestation 
Low Birth Weight (Yes/No)  ~ Maternal NAA – AD (Yes/No) | other predicting factors 
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3.1.2 NON – ASTHMATIC ATOPY (NAA) AND PREGNANCY OUTCOMES BY 
RACE/ETHNICITY 
 
 This study seeks to determine if maternal race/ethnicity; White Non – Hispanic (WNH) or 
Black Non – Hispanic (BNH), modifies the effect of NAA on adverse pregnancy outcomes.  
 
Research Question 2 
Does maternal race/ethnicity modify the adverse effect of NAA on pregnancy outcomes? 
 
Example of Models to be fit: 
iii) Among WNH women and BNH women separately 
SGA (Yes/No) ~ Maternal NAA – AD (Yes/No) | other predicting factors 
 PTB (Yes/No) ~ Maternal NAA – AR (Yes/No) | other predicting factors 
 
3.1.3 STUDY POPULATION 
The study population is comprised of primiparous women between the ages of 19 and 25.  
 
3.1.4 INCLUSION CRITERIA 
 The women included in this study were primiparous and between the ages of 19 and 25 years 
old. 
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3.1.5 EXCLUSION CRITERIA 
 Excluded from this study were women who were, younger than 19 years old or older than 
25 years. Women were also excluded if they were multiparous or had a plural birth. In addition to 
this, fetuses born before the completion of 24 weeks of gestation were excluded. 
 
3.1.6 DATA SOURCES 
An administrative database was used in order to generate a higher absolute number of 
mothers with the disorders being studied. The database that was used to answer the research 
question was identified retrospectively using South Carolina’s MEDICAID database. These claims 
were linked to births occurring between January 1, 2004 and January 1, 2014 identified in South 
Carolina’s Vital Statistics records.  
 
3.1.7 DEFINITION AND MEASUREMENT OF EXPOSURE AND OUTCOMES 
The diagnosis being measured is non – asthmatic atopy (NAA). Women were classified as 
having the diagnosis or not. Women were classified as having NAA using ICD – 9 code 477 for 
allergic rhinitis (AR) and/or ICD – 9 codes 691 and 692 for atopic dermatitis (AD) at least 1 year 
prior to pregnancy. Births from the women identified were matched to State birth records to classify 
the outcome of the pregnancy. Additional information that was extracted from the database include 
maternal characteristics that serve as possible confounders. These include diagnoses of asthma, 
hypertension and diabetes. Additional confounding demographic and risk factors that were 
extracted include race/ethnicity and smoking.  
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Mothers with the diagnosis being studied, NAA, were frequency matched to 4 unexposed 
mothers according to age, sex of the infant born and a diagnosis of asthma. 
The outcomes being investigated in this study are low birth weight (LBW), small for 
gestational age (SGA) and preterm birth (PTB). Infants were classified as: having low birth weight 
(LBW) if their birth weight was less than 2500g. Infants with a birth weight less than the 2 standard 
deviations from the sex – and gestational age – specific mean of the dataset were classified as being 
SGA. While births occurring before completion of the 37th week of gestation were classified as a 
preterm birth (PTB).  
 
3.1.8 STATISTICAL ANALYSIS 
Statistical analysis was conducted using STATA version 12 (StataCorp, 2011). Each 
individual contributed a single observation (only first pregnancy) to the analysis and therefore 
standard methods for data analysis on numeric outcomes and categorical outcomes were employed. 
In the first instance, data was summarized. Then bivariate associations were measured using T – 
tests, Chi – Square tests or Fisher’s exact tests depending on tabulation frequencies. Associations 
found were quantified using Poisson regression models.  
 
3.1.9 SAMPLE SIZE AND POWER 
In order to be sufficiently able to measure a change in risk, the sample must have adequate 
power to detect this change (see Tables 1 – 6).  
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Using a population prevalence rate for low birth weight of 8% (CDC, 2014b) the tables 
below show the required sample size with corresponding power to detect various multiples of risk of 
the outcome in the exposed population.  
Using the MEDICAID database, there was sufficient sample size to have 85% power to detect 
a 50% increase as well as 80% power to detect a 40% reduction in the risk of low birth weight 
(LBW), using a matching ratio of 1 diagnosed NAA mother to 4 NAA undiagnosed controls.  
Using a population prevalence rate for preterm birth (PTB) of 12.5% (CDC, 2014b) the 
tables below shows the required sample size with corresponding power to detect various multiples 
of risk of the outcome in the exposed population.  
Using the MEDICAID database, there should be a sufficient sample size to have 90% power 
to detect a 50% increase as well as a 40% reduction in risk of preterm birth, using a matching ratio 
of 1 diagnosed NAA mothers to 4 NAA undiagnosed controls. 
 
3.2 REGULATORY PERMISSIONS  
This study, ID Pro00020127, was approved by the University of South Florida’s Institutional Review 
Board (IRB) (Appendix J). In addition, permission was also obtained from the South Carolina 
Department of Health and Environmental Control to use their Medicaid and Vital Statistics records 
(Appendix K). 
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3.3 CHAPTER THREE TABLES AND FIGURES 
 
 
Table 1:  Sample Size Calculation for Low Birth Weight; matching ratio 1:1 
Increased 
Risk 
Power 
80% 85% 90% 
 exposed controls Exposed Controls exposed controls 
2x 283 283 320 320 370 370 
1.5x 932 932 1058 1058 1230 1230 
0.6x 979 979 1111 1111 1290 1290 
Population LBW prevalence = 8.0% 
Type I error rate = 5% 
 
 
 
 
 
Table 2: Sample Size Calculation for Low Birth Weight; matching ratio 1:2 
Increased 
Risk 
Power 
80% 85% 90% 
 Exposed controls exposed controls exposed controls 
2x 204 408 233 466 271 542 
1.5x 682 1364 779 1558 911 1822 
0.6x 755 1510 851 1702 981 1962 
Population LBW prevalence = 8.0% 
Type I error rate = 5% 
 
 
Table 3:  Sample Size Calculation for Low Birth Weight; matching ratio 1:4 
Increased 
Risk 
Power 
80% 85% 90% 
 Exposed controls exposed Controls exposed controls 
2x 164 256 188 752 221 884 
1.5x 557 2228 639 2556 750 3000 
0.6x 641 2564 719 2876 824 3296 
Population LBW prevalence = 8.0% 
Type I error rate = 5% 
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Table 4: Sample Size Calculation for Preterm Birth; matching ratio 1:1 
Increased 
Risk 
Power 
80% 85% 90% 
 exposed controls exposed Controls exposed Controls 
2x 168 168 190 190 219 219 
1.5x 561 561 637 637 739 739 
0.6x 604 604 685 685 794 794 
Population PTB prevalence = 12.5% 
Type I error rate = 5% 
 
 
Table 5: Sample Size Calculation for Preterm Birth; matching ratio 1:2 
Increased 
Risk 
Power 
80% 85% 90% 
 exposed controls exposed Controls exposed controls 
2x 122 244 139 278 161 322 
1.5x 412 824 469 938 548 1096 
0.6x 465 930 524 1048 604 1208 
Population PTB prevalence = 12.5% 
Type I error rate = 5% 
 
 
Table 6: Sample Size Calculation for Preterm Birth; matching ratio 1:4 
Increased 
Risk 
Power 
80% 85% 90% 
 exposed controls exposed Controls exposed controls 
2x 98 392 112 448 132 528 
1.5x 336 1344 385 1540 452 1808 
0.6x 394 1576 442 1768 507 2028 
Population PTB prevalence = 12.5% 
Type I error rate = 5% 
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CHAPTER FOUR: RESULTS 
 
4.1 SUMMARY OF SAMPLE CHARACTERISTICS 
 The Medicaid database contained 67,281 unique maternal records. The Vital Statistics 
database contained 67,771 infant outcomes. During data cleaning some records from the infant 
outcomes were excluded. These were 1,369 records from plural births, 543 records with information 
on plurality missing, 165 records with gestational ages at birth less than 24 weeks, 38 records with 
gestational age at birth missing and 8 records with infant birth weight missing (see Appendix E, 
Figure 13). This left 65,650 infant outcomes which were then linked to the 67,281 maternal records 
using a unique identifier present in both databases. This formed 65,650 (97.5% of the 67,281 
maternal records) complete maternal – infant dyads for analysis. Of these 65,650 mother – infant 
dyads there were 1,993 diagnosed with NAA who were frequency matched 1:4 to undiagnosed 
controls on maternal age, maternal diagnosis of asthma and infant sex. The dataset used in the 
primary analysis contained the 9,965 matched records (see Appendix E, Figure 14).   
Table 26 (see Appendix F) provides a summary of the International Classification of Disease 
Codes (ICD – 9) used in this study.   
Mothers’ ages ranged from 19 to 25 years with a mean of 20.8 yrs. (see Appendix F, Table 
27). There were 1,993 (20.0%) mothers with a diagnosis of non – asthmatic atopy (NAA) and 7,972 
unexposed controls (Table 7). One thousand and ninety three (11.1%) mothers had a diagnosis of 
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allergic rhinitis (AR) and 959 (9.6%) had a diagnosis of atopic dermatitis (AD) (Table 7). Infants’ 
gestational ages at birth ranged from 24 to 43 weeks with a mean of 38.6 weeks. Infants’ birth weights 
ranged from 140 to 6,719 grams with a mean of 3,155.1 grams (see Appendix F, Table 27). The 
number of non – asthmatic atopy diagnoses among mothers ranged from 0 to 4 (see Appendix F, 
Table 27).  
Figure 1 displays the percentage of mothers with NAA across infant birth weight. Non – 
asthmatic atopy (AR and AD combined), along with AR (considered separately) (see Appendix G, 
Figure 15) and AD (considered separately) (see Appendix G, Figure 16), all displayed a significant 
increasing trend across birth weight categories. Approximately 16% of infants born, weighing less 
than 1,000 grams, had mothers with NAA compared to 20% of infants born weighing 2,500 grams 
or more (Figure 1).  Figures 15 and 16 (see Appendix G) also show that among mothers who had 
heavier infants at birth, higher percentages were diagnosed with AR and AD. While asthma 
displayed a significant decreasing trend across birth weight (Figure 2). Mothers with heavier infants 
at birth had lower percentages with asthma. Figure 3 displays the percentage of mothers with NAA 
across gestational ages at birth categories. There is a significant increasing trend across gestational 
age at birth. Mothers who gave birth later had higher percentages with NAA. Approximately 14% 
of infants born between 24 and 27 weeks of gestation, had mothers with NAA compared to 20% of 
those born after completing at least 36 weeks of gestation. Figure 4 displays the percentage of 
mothers with NAA across fetuses at risk for each gestational age (i.e. fetuses who were born with a 
greater gestational age). There is a significant overall increasing trend as well as a significant 
increasing trend up to 36 weeks of gestation. After 40 weeks of gestation, the percentage of mothers 
with NAA decreases. Figure 17 (see Appendix G) displays the percentage of mothers with AR across 
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gestational ages at birth categories. There is a significant increasing trend across gestational age at 
birth. Mothers who gave birth later had higher percentages with AR. Figure 18 (see Appendix G) 
displays the percentage of mothers with AR across fetuses at risk for each gestational age. There is a 
significant overall increasing trend as well as a significant increasing trend up to 36 weeks of 
gestation. Figure 19 (see Appendix G) displays the percentage of mothers with AD across gestational 
ages at birth categories. There is a significant increasing trend across gestational age at birth. Mothers 
who gave birth later had higher percentages with AD. Figure 20 (see Appendix G) displays the 
percentage of mothers with AD across fetuses at risk for each gestational age. There is a significant 
overall increasing trend as well as a significant increasing trend up to 36 weeks of gestation. Figure 
5 displays the percentage of mothers with asthma across gestational ages at birth categories. There is 
a significant decreasing trend across gestational age at birth. Mothers who gave birth later had lower 
percentages with asthma. Figure 6 displays the percentage of mothers with asthma across fetuses at 
risk for each gestational age. There is a significant overall increasing trend as well as a significant 
increasing trend up to 36 weeks of gestation.  
There were slightly more males born (51.6%) than females (48.4%) (see Appendix F, Table 
28). The sample included 4,607 (46.3%) White non – Hispanic (WNH) mothers, 4,556 (45.7%) 
Black non – Hispanic mothers (BNH), 698 (7.0%) Hispanic mothers, and 100 (1.0%) mothers who 
were of another race/ethnicity or whose race/ethnicity was given as other (see Appendix F, Table 
28). Approximately one – fifth (19.5%) of women reported smoking prior to pregnancy, while 14.7% 
reported smoking during pregnancy (see Appendix F, Table 28). Pre – pregnancy diabetes was 
reported in 0.7% of women, while almost 5 times as many (3.3%) were reported to have gestational 
 27 
 
diabetes. Pre – pregnancy hypertension was reported among 2.0% of women and 15.5% had a 
previous diagnosis of asthma (see Appendix F, Table 28).   
Among infants born at term; at least 37 weeks of gestation, the percent with LBW was 4.4% 
(Table 8). The percent of infants born SGA was 2.0% in this sample and the percent of PTB; infants 
born before completing 37 weeks of gestation was 9.5%.  
 
4.2 SUMMARY OF CHARACTERISTICS BY ATOPY CATERGORY 
 
4.2.1 NON – ASTHMATIC ATOPY (NAA) 
 Table 29 (see Appendix F) shows the distributions of age of mother, gestational age of infant 
at birth and infant birth weight.  There was no difference in mean gestational age at birth or infant 
birth weight among mothers with NAA and those without. There was a lower proportion of mothers 
with NAA who were of Hispanic ethnicity when compared to the proportion of mothers without 
NAA who were of Hispanic ethnicity (3.3% vs. 7.9% resp.; p < 0.001), while there were almost equal 
proportions of WNH and BNH mothers in either atopy category (see Appendix F, Table 30). The 
percent of mothers who smoked prior to pregnancy was higher among mothers with NAA compared 
to those without NAA (21.4% vs. 19.0%; p < 0.05). While the percent of mothers who smoked 
during pregnancy, had pre – pregnancy diabetes, gestational diabetes, pre – pregnancy hypertension 
and asthma; was similar across NAA diagnosis (see Appendix F, Table 30).  
There was no difference in distribution of study outcomes, LBW, SGA or PTB among 
mothers with NAA and those without (Table 9).   
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The distribution of characteristics were similar when examined as type of NAA i.e. Allergic 
Rhinitis (AR) and Atopic Dermatitis (AD) (see Appendix F, Table 31). A maternal diagnosis of 
asthma and maternal race/ethnicity were significantly associated with type of NAA (Table 10). There 
was a higher proportion of mothers with asthma among patients with AR when compared to those 
without (21.2% vs. 14.8% resp.; p < 0.001) (Table 10). The relationship between asthma and AD 
was reversed, a smaller proportion of mothers with AD also had asthma when compared to those 
who did not have AD (10.4% vs. 16.1% resp.; p < 0.001) (Table 10).  
A higher proportion of mothers with AR were WNH compared to the proportion of those 
who did not have AR (52.3% vs. 45.5% resp.) (Table 10). This pattern was reversed for mothers of 
other ethnicities; BNH (44.7% vs. 45.9% resp.), Hispanic (2.6% vs. 7.6% resp.) and other (0.4% vs. 
1.1% resp.). Among mothers with AD a larger proportion were BNH when compared to the 
proportion of mothers without AD who were (52.9% vs. 45.0%). Again this pattern was reversed 
among mothers of other ethnicities; WNH (42.4% vs. 46.7% resp.), Hispanic (4.0% vs. 7.3% resp.) 
and other (0.7% vs. 1.0% resp.).  
Table 11 shows the distribution of study outcomes across atopy type. 
 
4.2.2 ASTHMA 
 Mothers who had previously been diagnosed with Asthma were similar in age to those who 
had not previously been diagnosed with asthma (see Appendix F, Table 29). The mean gestational 
age at birth was slightly lower among mothers who had been previously diagnosed with asthma when 
compared to those who had not (38.4 weeks vs. 38.6 weeks, p < 0.001). Infants born to mothers with 
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asthma weighed less than those born to mothers without asthma (3096.6 g vs. 3166.7 g, p < 0.001) 
(see Appendix F, Table 29).  
There was a higher proportion of BNH mothers with asthma compared to the proportion of 
BNH mothers without asthma (51.5% vs. 44.7% resp.) (see Appendix F, Table 30). While a smaller 
proportion of mothers with asthma were Hispanic than the proportion of mothers without asthma 
who were (3.6% vs. 7.6% resp.). The percent who smoked prior to pregnancy was higher among 
mothers with asthma compared to mothers without (23.4% vs. 18.8% resp.; p < 0.001). This was 
also true of smoking during pregnancy (18.8% vs. 14.0% resp.; p < 0.001). The percent with pre – 
pregnancy diabetes was higher among mothers with asthma than it was among mothers without 
asthma (1.3% vs. 0.6% resp.; p < 0.05), while the percent with gestational diabetes was similar for 
both groups of women. Pre – pregnancy hypertension was also higher among mothers with asthma 
when compared to those without asthma (3.1% vs. 1.8%; p < 0.05) (see Appendix F, Table 30).  
Table 9 shows the associations between study outcomes and asthma. Birth weight when 
explored as extremely low birth weight (less than 1,000g), very low birth weight (1,000 – 1,499g), 
moderately low birth weight (1,500 – 2,499g), normal birth weight (2,500 – 3,999g) and high birth 
weight (4,000g or more); did display a significant association with having a diagnosis of asthma or 
not. However when birth weight was explored as simply low birth weight (less than 2,500g) among 
infants born at term (at least 37 weeks of gestation), there was no association with a diagnosis of 
asthma. There was also no association found between infants born SGA and mothers with a previous 
diagnosis of asthma or not. The percent of preterm birth was higher among mothers with a diagnosis 
of asthma when compared to those without (11.5% vs. 9.1% resp.) 
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4.2.3 NAA AND ASTHMA  
 Table 12 displays the results of examining the association between asthma and study 
outcomes in the presence of absence of NAA. The percent of LBW and PTB were similarly 
distributed across asthma categories in the presence or absence of NAA. The percent of SGA was 
lowest among asthmatic women who also had NAA and highest among women who had asthma 
only.   
The association between asthma and study outcomes when examined across NAA type is 
displayed in Tables 32 and 33 (see Appendix F, Tables 32 and 33). In the presence of AR the percent 
of LBW among asthmatic mothers was slightly lower than the percent of LBW among non – 
asthmatic mothers. This result was not significant.  
The percent of SGA is lower among asthmatic mothers with AR and mothers with neither 
complaint than it was among non – asthmatic mothers with AR and asthmatic mothers without AR. 
This again did not achieve statistical significance.  
In the presence of AR, the percent of preterm birth was higher among asthmatic mothers 
when compared to non – asthmatic mothers (12.5% vs 8.5% resp.; p < 0.10). The percent of PTB 
was lowest among mothers who had AR only and highest among mothers with both disorders. 
The percent of LBW was similar across asthma categories (see Appendix F, Table 33). In the 
presence of AD the percent of LBW among asthmatic women increases and tended towards being 
significantly different from the percent with LBW among mothers with AD only.  
A similar pattern was seen with the percent of SGA. In the presence of AD the percent of 
SGA among asthmatic and non – asthmatic women was 3.0% and 1.8% resp. However this result 
did not achieve statistical significance. 
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The percent of preterm birth was similar among mothers with asthma and mothers without 
asthma provided mothers had a diagnosis Atopic Dermatitis, although the percent of PTB among 
asthmatic mothers was slightly higher (10.1% vs. 9.3%). When there was no diagnosis of Atopic 
Dermatitis, the percent of PTB was higher among mothers with asthma compared to mothers 
without asthma (11.6% vs. 9.1% resp.). 
 
4.3 MULTIVARIABLE MODELING  
 Table 13 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from Poisson 
regression models predicting an outcome of LBW among infants born after completing at least 37 
weeks of gestation. Mothers with NAA had a reduced risk of having an infant with LBW (RRA = 
0.96; p > 0.10) when compared to mothers who did not have NAA. While mothers with asthma had 
an increased risk of having an infant born LBW (RRA = 1.05; p > 0.10) when compared to mothers 
who do not. 
Female infants are more likely to be born LBW compared to male infants (RRA = 1.43; p < 
0.001). Infants born to BNH mothers are more likely to be born LBW when compared to WNH 
mothers (RRA = 2.307; p < 0.001). There was no significant difference in the risk of LBW among 
infants born to Hispanic mothers when compared to WNH mothers (RRA = 1.18; p > 0.10). Infants 
born to mothers of “other” ethnicity had an increased risk of LBW compared to infants born to 
WNH mothers (RRA = 2.712; p = 0.010). Mothers who smoked during pregnancy were more likely 
to give birth to LBW infants (RRA = 1.813; p < 0.001) compared to those who did not smoke during 
pregnancy.  
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Table 14 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from Poisson 
regression models predicting an outcome of SGA. Mothers with NAA had a reduced risk of having 
an infant who was SGA when compared to mothers without NAA (RRA = 0.94; p > 0.10). While 
mothers with asthma had increased risk of having an infant born SGA (RRA = 1.11; p > 0.10) when 
compared to those who did not have asthma. 
Older mothers were more likely to have infants born SGA (RRA = 1.06; p < 0.10). Infants 
born to BNH mothers are more likely to be born SGA when compared to WNH mothers (RRA = 
1.85; p < 0.001). There was no significant difference in the risk of SGA among Hispanic mothers 
when compared to WNH mothers (RRA = 0.98; p > 0.10). Infants born to mothers of “other 
ethnicity” had an increased risk of SGA when compared to WNH mothers (RRA = 2.69; p < 0.10). 
Mothers who smoked during pregnancy were more likely to have infants born SGA when compared 
to mothers who did not smoke during pregnancy (RRA = 2.09; p < 0.001). Mothers who had pre – 
pregnancy hypertension were more likely to have an infant born SGA when compared to mothers 
who did not have pre – pregnancy hypertension (RRA = 2.45; p < 0.001).    
Table 15 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from Poisson 
regression models predicting an outcome of PTB. Mothers with NAA had reduced risk of having a 
PTB when compared to mothers without NAA (RRA = 0.95; p > 0.10). While mothers with asthma 
had increased risk of having a PTB (RRA = 1.20; p = 0.03) when compared to those who did not 
have asthma. 
BNH mothers were more likely to have a PTB when compared to WNH mothers (RRA = 
1.32; p < 0.001). Hispanic mothers were less likely than WNH mothers to have a PTB (RRA 0.59; p 
< 0.05). There was no significant difference in the risk of PTB among mothers of “other” ethnicity 
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when compared to WNH mothers (RRA 0.96; p > 0.10). Mothers who had gestational diabetes were 
more likely to have a PTB compared to mothers who did not have gestational diabetes (RRA = 1.61; 
p < 0.05). Mothers who had pre – pregnancy hypertension were more likely to have a PTB when 
compared to mothers who did not have pre – pregnancy hypertension (RRA = 2.68; p < 0.001).  
 
4.4 SUMMARY OF SAMPLE CHARACTERISTICS BY RACE/ETHNICITY 
 There were 4,607 white non – Hispanic (WNH) women and 4,556 black non – Hispanic 
(BNH) women from whom data was further analyzed. Table 16 shows the distribution of NAA 
among WNH women and BNH women. Allergic rhinitis (AR) was more prevalent among WNH 
women when compared to BNH women (12.4% vs. 10.7%; p < 0.05) while atopic dermatitis (AD) 
was more prevalent among BNH women when compared to WNH women (11.1% vs. 8.8%; p < 
0.001).  
Figure 7 displays the percent of mothers with an atopic disorder by infant birth weight by 
maternal race/ethnicity. Non – asthmatic atopy (NAA) displayed a significant increasing trend with 
infant birth weight for both WNH and BNH mothers (Figure 7). 11% of WNH mothers and 18% 
of BNH mothers who had infants weighing less than 1,000 grams at birth, also had NAA compared 
to 20% of those weighing 2,500 grams or more at birth, for both sets of mothers (Figure 7). Appendix 
G, Figures 21 and 22 display the percent of mothers with AR and AD respectively by infant birth 
weight for both WNH and BNH mothers. Both AR and AD displayed a significant increasing trend 
with infant birth weight for both sets of women. While asthma displayed a significant decreasing 
trend with birth weight across maternal race/ethnicity. Both WNH and BNH mothers who had 
smaller infants at birth had higher percentages with asthma (Figure 8).  
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Figure 9 displays the percent of mothers with NAA across infant gestational age at birth by 
maternal race/ethnicity. There was a significant increasing trend with infant gestational age at birth 
for both WNH and BNH mothers. Mothers with higher percentages of NAA gave birth to infants 
with greater gestational ages at birth. 11% of WNH mothers and 16% of BNH mothers whose 
infants were born between 24 and 27 weeks of gestation, also had NAA compared with 21% of those 
born after completing at least 36 weeks of gestation among both sets of women. Figure 10 displays 
the percent of mothers with NAA across fetuses at risk for each gestational age (i.e. fetuses who were 
born with a greater gestational age) by maternal race/ethnicity. There is a significant overall 
increasing trend as well as a significant increasing trend up to 36 weeks of gestation for both WNH 
and BNH mothers. Figure 23 (see Appendix G) displays the percent of mothers with AR across 
gestational age at birth by maternal race/ethnicity. There is a significant increasing trend with 
gestational age at birth for both WNH and BNH mothers. Mothers with higher percentages of AR 
gave birth to infants with greater gestational ages at birth. Figure 24 (see Appendix G) displays with 
percentage of mothers with an AR across fetuses at risk for each gestational age by maternal 
race/ethnicity. There is a significant overall increasing trend as well as a significant increasing trend 
up to 36 weeks of gestation for both WNH and BNH mothers. Figure 25 (see Appendix G) displays 
the percent of mothers with AD across gestational age at birth by maternal race/ethnicity. There is 
a significant increasing trend with gestational age at birth for WNH mothers, while the trend is 
significant but decreasing among BNH mothers. WNH mothers with higher percentages of AD gave 
birth to infants with greater gestational ages at birth, while BNH mothers with higher percentages 
of AD gave birth to infants with shorter gestational ages at birth. Figure 26 (see Appendix G) displays 
the percentage of mothers with AD across fetuses at risk for each gestational age by maternal 
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race/ethnicity. There is a significant overall increasing trend as well as a significant increasing trend 
up to 36 weeks of gestation for both WNH and BNH mothers. Figure 11 displays the percent of 
mothers with asthma across gestational age at birth by maternal race/ethnicity. There is a significant 
decreasing trend with gestational age at birth for both WNH and BNH mothers. Mothers who 
delivered earlier had higher percentages with asthma. Figure 12 displays with percentage of mothers 
with asthma across fetuses at risk for each gestational age by maternal race/ethnicity. There is a 
significant overall increasing trend as well as a significant increasing trend up to 36 weeks of gestation 
for both WNH and BNH mothers. 
Primiparous WNH mothers were slightly older than BNH mothers (see Appendix F, Table 
34). Infants born to primiparous WNH mothers tended to have a greater gestational age at birth 
and birth weight compared to infants born to primiparous BNH (see Appendix F, Table 34). The 
percent of mothers who smoked both prior to (32.1% vs. 8.7%; p < 0.001) and during (25.0% vs. 
6.0%) pregnancy was much higher among WNH women when compared to BNH women (see 
Appendix F, Table 35). The percent of mothers who had pre – pregnancy diabetes (0.5% vs. 0.9%; 
p < 0.05), and pre–pregnancy hypertension (1.4% vs. 2.8%; p < 0.001) were lower among WNH 
women compared to BNH women (see Appendix F, Table 35). While gestational diabetes was 
slightly lower among WNH, the percent with same among BNH was comparable (3.0% vs. 3.6%; p 
< 0.10).  
Across both ethnicities, comparing mothers with NAA to mothers without NAA did not 
display significant results for age and gestational age at birth (see Appendix F, Table 36). WNH 
mothers with NAA gave birth to heavier infants when compared to WNH mothers without NAA (p 
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< 0.10). There was no difference in the birth weights of infants born to BNH mothers with or 
without NAA.  
Study outcomes were all disproportionately distributed across maternal race/ethnicity (Table 
17). The percent of infants born LBW among infants born to BNH mothers was twice that of the 
percent of same born to WNH mothers (6.0% vs. 3.0%; p < 0.001). A Similar trend in SGA was 
seen (2.5% vs. 1.6%; p < 0.001) and PTB (11.3% vs. 8.4%; p < 0.001). 
The percent of WNH mothers with NAA who had pre – pregnancy hypertension was higher 
than the percent of WNH others without NAA who had pre – pregnancy hypertension (2.0% vs. 
1.2%; p < 0.10) (see Appendix F, Table 37). The distributions of other characteristics were similar 
across NAA category for both ethnicities (see Appendix F, Table 37). 
 
4.5 SUMMARY OF CHARACTERISTCS BY ATOPY TYPE BY RACE/ETHNICITY 
 
4.5.1 ASTHMA 
 The prevalence of asthma was lower among WNH women when compared to BNH 
women (14.9% vs. 17.5%; p < 0.05; Appendix F, Table 35). The prevalence of asthma however, 
was comparable when comparing mothers with and without NAA for each race/ethnicity (see 
Appendix F, Table 37). Study outcomes did not differ across NAA category for mothers of either 
race/ethnicity (Table 18).     
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4.5.2 NAA AND ASTHMA 
 Table 19 shows the results of examining the interaction of asthma and NAA more closely 
among WNH women and its effect on study outcomes.  
The percent of infants born LBW was elevated among WNH women with asthma compared 
those without asthma (3.9% and 2.8%; Table 19). Once asthma was excluded, the remaining WNH 
mothers with NAA had lower, albeit slightly lower, percentages of infants born LBW (2.6% and 
2.9%; Table 19). However, in the presence of asthma, NAA appears to exacerbate the risk of LBW. 
The percent of infants born LBW was 4.4% and 3.9% (Table 19) among WNH asthmatic women 
with and without AD respectively.  
This trend was also present for SGA among WNH mothers (Table 19). The percent of 
infants born SGA to WNH mothers who had asthma was slightly higher than that among WNH 
mothers who did not have asthma (2.3% vs. 1.5%; p < 0.10). Again, if asthma were excluded the 
remaining WNH mothers with NAA had slightly lower percentages of infants born SGA (1.3% and 
1.5% respectively among non – asthmatics with and without NAA). However once asthma was 
present, the percent of infants born SGA appeared to be increased if the mother also had NAA. The 
percent of infants born SGA was 2.2% among WNH mothers with asthma only and 3.2% among 
WNH who had asthma along with NAA.  
The percent of PTB was slightly higher among WNH mothers who had asthma when 
compared to those who did not (10.1% vs. 8.1%; p < 0.10) (Table 19). Among those who did not 
have asthma, those with NAA had a lower percent of PTB, 7.3% and 8.3% respectively among non 
– asthmatics with and without NAA. Once asthma was present NAA did not affect the percent of 
PTB.   
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 The asthma and NAA interaction appeared to have a different effect among BNH mothers 
(Table 20). For each study outcome the highest percentages occurred among BNH women with 
asthma only.    
The percent of infants born LBW was similar among BNH mothers with or without asthma 
(5.9% and 6.0%; Table 20). However, asthmatic mothers appeared to receive protection against 
LBW if they also had NAA. The percent of infants born LBW among asthmatics was lower if the 
mother also had NAA, 4.8% and 6.2% respectively among BNH asthmatic women with and without 
NAA. In the absence of asthma the protection provided by NAA was slight. The percent of infants 
born LBW among non – asthmatic women was 5.8% and 6.1% respectively for those with NAA and 
those without.    
The percent of infants born SGA was similar among BNH mothers with or without asthma 
(2.5%; Table 20). And further among those without asthma there was no variation in the percent of 
PTB with or without NAA. However among those with asthma there was a lower percent of infants 
born SGA among those with NAA compared to those without, 0.6% and 3.0% respectively for 
asthmatic BNH women with and without NAA. 
There was a higher percent of PTB among BNH women with asthma compared to those 
without (13.0% and 11.0%; Table 20). While NAA did not affect the percent of PTB among non – 
asthmatics, it appeared to protect asthmatic women from PTB. The percent of PTB among BNH 
asthmatic mothers was 12.1% and 13.2% respectively among those with NAA and those without.   
Looking more closely at the interaction between asthma and type of NAA by race/ethnicity 
continued to reveal some variations. Table 38 (see Appendix F) shows the distributions of study 
outcomes and the interaction of asthma and AR among WNH women.  
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In the absence of asthma, WNH women with AR had lower percentages of infants born 
LBW compared to those without AR i.e. those with no atopy (2.5% and 2.8%; see Appendix F, 
Table 38). However, once asthma was present the percent of infants born LBW was higher (4.4%) 
among mothers who also had AR compared to those with asthma only (3.8%). 
This trend was also present for SGA among WNH mothers. The percent of infants born 
SGA among WNH mothers who had asthma was slightly higher than that among WNH mothers 
who did not have asthma (2.3% vs. 1.5%; p < 0.10; see Appendix F, Table 38). The percent of infants 
born SGA was slightly lower among non – asthmatic WNH mothers with AR compared to those 
without AR i.e. those with no atopy (1.3% and 1.5%). When asthma was present, the percent of 
infants born SGA appeared to be increased if the mother also had AR. The percent of SGA was 
2.2% among WNH mothers with asthma only and 3.0% among WNH who had both asthma and 
AR. 
AR did appear to reduce the percent of PTB among both asthmatic and non – asthmatic 
WNH women (see Appendix F, Table 38). The percent of PTB among WNH asthmatic women was 
9.9% and 10.1% respectively for those with and without AR. While the percent of PTB was 7.6% 
and 8.2% respectively among non – asthmatic with and without AR.  
AR in the presence of asthma appeared to have a different effect among BNH mothers (see 
Appendix F, Table 39). The percent of infants born LBW was similar among BNH mothers with or 
without asthma (5.9% and 6.0%). Among BNH mothers with asthma, the percent of infants born 
LBW was lower among those with AR compared to those without AR (2.9% and 6.4%). However 
the percent of infants born LBW appeared was greater among non – asthmatic women with AR 
compared to those no atopy (6.9% and 5.9%).    
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The percent of infants born SGA was similar among BNH mothers with or without asthma 
(2.5%; see Appendix F, Table 39). However the percent of infants born SGA was lowest among 
asthmatic BNH mothers who had AR (0.6%) and this percent was lower than that among asthmatic 
BNH mothers without AR (2.8%). The highest percent of infants born SGA was among non – 
asthmatic BNH women with AR (3.5%) and this percent was higher than among BNH with no 
atopy (2.4%).  
The percent of PTB among BNH mothers with asthma appeared to be made worse by the 
presence of AR (see Appendix F, Table 39). The percent of PTB was 15.0% and 12.6% respectively 
among BNH asthmatic women with and without AR. Once asthma was excluded, the remaining 
BNH mothers had lower percentages of PTB if they also had AR compared to those who had no 
atopy (10.1% and 11.1%).   
Examining how the interaction between asthma and atopic dermatitis (AD) affects study 
outcomes among WNH mothers is shown in Table 40 (see Appendix F).  
The percent of infants born LBW was higher among WNH mothers who asthma compared 
to those who did not (see Appendix F, Table 40). AD appeared to exacerbate the effect of asthma 
on the percent of infants born LBW. Among asthmatic women, 10.0% and 3.6% had infants born 
LBW among those with AD and those without AD respectively. Again once asthma was excluded, 
there was slightly lower percent of infants born LBW among mother with AD compared to among 
those with no atopy (2.6% and 2.8% respectively). 
A similar exacerbating trend was observed for infants born SGA among WNH women (see 
Appendix F, Table 40). The percent of infants born SGA was higher among asthmatic WNH with 
AD compared to those without AD (9.1% and 2.0% respectively). Again, once asthma was excluded, 
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WNH mothers with AD only had slightly lower percentages of infants born SGA compared to 
mothers with no atopy (1.3% and 1.5%, respectively) 
The lowest percent of PTB among WNH mothers, was among those without asthma but 
with AD (7.0%) this compared to those no atopy (8.2%). And among asthmatic WNH mothers 
those with AD had a lower percent of PTB compared to those without (9.1% and 10.1% 
respectively).  
 Examining how the interaction between asthma and AD affects study outcomes among BNH 
mothers is shown in Table 41 (see Appendix F).  
AD appears to exacerbate the effect that asthma had on LBW among BNH mothers. The 
percent of infants born LBW is 9.1% and 5.6% among asthmatics with and without AD respectively. 
However it appears that once asthma is excluded AD is protective against LBW. The percent of 
infants born LBW is 5.3% and 6.1% among non – asthmatics with AD and those with no atopy 
respectively. 
While there was no difference between the percent of BNH mothers who had infants born 
SGA among those with asthma and those without asthma, AD appears to protect against SGA (see 
Appendix F, Table 41). The percentages of infants born SGA were lower among mothers who had 
AD (0% and 2.0% respectively among asthmatics and non – asthmatics) when compared to the 
percentages among mothers who did not have AD (2.7% and 2.6% respectively for asthmatics and 
non – asthmatics). 
The highest percent of PTB occurred among BNH mothers who had asthma only (13.2%) 
compared to those who had both asthma and AD (10.0%; see Appendix F, Table 41). However, 
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when asthma was not present, BNH women with AD had higher percentages with PTB compared 
to those without (11.7% and 10.9% respectively for non – asthmatics with and without AD).   
 
4.6 MULTIVARIABLE MODELING BY RACE/ETHNICITY 
 Table 21 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from separate 
Poisson regression models predicting an outcome of LBW among infants born after completing at 
least 37 weeks of gestation to WNH and BNH mothers. Mothers with NAA had a reduced risk of 
having an infant born LBW compared to those without NAA (RRA = 0.95 and 0.94 for WNH and 
BNH resp.; p > 0.10). While WNH mothers with asthma had an increased risk of having an infant 
born LBW (RRA = 1.29; p > 0.10) and BNH mothers with asthma had a reduced risk of having an 
infant born LBW (RRA = 0.96; p > 0.10); compared to those without asthma. 
Female infants born to BNH mothers were more likely to be born LBW compared to male 
infants (RRA = 1.66; p < 0.001). While smoking during pregnancy increased the risk of infants being 
born LBW among WNH mothers (RRA = 2.03; p < 0.001). 
Table 22 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from separate 
Poisson regression models predicting an outcome of SGA among infants born to WNH and BNH 
mothers. Mothers with NAA had a reduced risk of having an infant born SGA compared to those 
without NAA (RRA = 0.97 and 0.84 for WNH and BNH resp.; p > 0.10). While WNH mothers with 
asthma had an increased risk of having an infant born SGA (RRA = 1.47; p > 0.10) and BNH mothers 
with asthma had a reduced risk of having an infant born SGA (RRA = 0.96; p > 0.10); compared to 
those without asthma. 
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Female infants born to WNH mothers were less likely to be born SGA compared to male 
infants (RRA = 0.51; p < 0.05). While increased age increased the risk of infants being born SGA 
among BNH mothers (RRA = 1.10; p < 0.10). Smoking during pregnancy increased the risk of infants 
being born SGA among WNH mothers (RRA = 2.22; p < 0.05). Pre – pregnancy hypertension 
increased the risk of infants being born SGA for both WNH and BNH mothers (RRA = 4.09 and 
2.03 resp.; p < 0.05 and p < 0.10 resp.). 
Table 23 shows the crude relative risks (RRC) and adjusted relative risks (RRA) from separate 
Poisson regression models predicting an outcome of PTB among infants born to WNH and BNH 
mothers. WNH mothers with NAA had a reduced risk of PTB, while BNH mothers with NAA had 
an equal risk of PTB compared to those without (RRA = 0.90 and 1.00 for WNH and BNH resp.; p 
> 0.10). While both WNH and BNH mothers with asthma had an increased risk of PTB (RRA = 
1.20 and 1.17 resp.; p > 0.10). 
BNH mothers with gestational diabetes were more likely than those without to have a PTB 
(RRA = 1.76; p < 0.05). Both WNH and BNH with pre – pregnancy hypertension were more likely 
to have a PTB than those without (RRA = 3.81 and 2.22 resp.; p < 0.001).  
 
4.7 SELECTED CONTROLS VS. REMAINING CONTROLS 
 There were a total of 63,657 potential controls. 7,972 were selected as controls (SC) and 
matched to mothers with NAA according to their ages, sexes of infants born and asthma diagnoses. 
The other 55,685 were the remaining controls (RC). Controls who were selected were slightly 
younger than controls who were not selected (mean = 20.8 vs. 21.2 yrs.; p < 0.001) (see Appendix F, 
Table 42). This would be expected as SC were matched to NAA diagnosed mothers on age. The 
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birth weights of infants born to SC were slightly lower than those of infants born to RC (mean = 
3,151.2 vs. 3,164.5g; p < 0.10). The sex of infants was similarly distributed across SC and RC. 
Maternal race/ethnicity was distributed differently among SC and RC (Table 24). The proportion 
of WNH mothers among controls selected was comparable to the proportion of BNH mothers 
among selected. While, among the controls who were not selected, there was a slightly higher 
proportion of WNH mothers compared to BNH mothers (Table 24). The percent of SC with asthma 
was much higher the percent of RC with asthma (Table 24). This would be expected as SC controls 
were also matched to NAA diagnosed women on asthma diagnosis. The percentages of SC who 
smoked prior to and during pregnancy were similar to the percentages of RC who smoked prior to 
and during pregnancy. The percent of SC with pre – pregnancy hypertension was slightly higher 
than the percent of RC with pre – pregnancy hypertension (2.0% vs. 1.7% resp.; p < 05).  
The percentages of all study outcomes; low birth weight, small for gestational age and 
preterm birth were similarly distributed among controls who were selected when compared to those 
who were not selected (Table 25).    
 
4.8 CHAPTER FOUR TABLES AND FIGURES 
 
Table 7: Summary of Atopy 
Exposure N (%) 
  
Non – Asthmatic Atopy 1,993 (20.0) 
  
Allergic Rhinitis (AR) 1,093 (11.0) 
  
Atopic Dermatitis (AD) 959 (9.6) 
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Table 8: Summary of Study Outcomes (N = 9,965) 
Characteristic n (%) 
  
Low birth weighta 394 (4.4) 
   
Small for gestational ageb 202 (2.0) 
   
Birth weight (grams)  
 Extremely lbw (< 1,000) 57 (0.6) 
 Very lbw (1,000 – 1,499) 92 (0.9) 
 Moderately lbw (1,500 – 2,499) 861 (8.7) 
 Normal bw (2,500 – 3,999) 8,468 (85.0) 
 High bw (4,000+) 481 (4.8) 
   
Preterm birth 944 (9.5) 
   
Gestational age at birth (weeks)  
 Extremely preterm (< 28) 55 (0.6) 
 Very preterm (28 – < 32) 94 (1.0) 
 Moderately preterm (32 – <37) 795 (8.0) 
 Term (37+) 9,003 (90.5) 
aFor infants born after completing 37 weeks of gestation, N = 9,017;  
bBirth weight less than 2 standard deviations from the sex – and gestational age – specific mean  
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Table 9: Study Outcomes by Atopy Category 
Characteristic Non–Asthmatic Atopy Asthma 
 Present/Cases Absent/Controls Present Absent 
 (N = 1,993) (N = 7,972) (N = 1,545) (N = 8,420) 
     
Low birth weighta     
 Yes 4.3% 4.4% 4.9% 4.3% 
Small for gestational ageb     
 Yes 2.0% 2.1% 2.4% 2.0% 
Birth weight (grams)   ** 
 Extremely LBW (< 1,000) 0.5% 0.6% 0.6% 0.6% 
 Very LBW (1,000 – 1,499) 0.7% 1.0% 1.4% 0.8% 
 Moderately LBW (1,500 – 2,499) 8.9% 8.7% 10.0% 8.4% 
 Normal  (2,500 – 3,999) 85.2% 85.0% 84.0% 85.2% 
 High (4,000+) 5.2% 4.8% 4.0% 5.0% 
Preterm birth   ** 
 Yes 9.3% 9.5% 11.5% 9.1% 
Gestational age at birth (weeks)   *** 
 Extremely preterm (< 28) 0.4% 0.6% 0.3% 0.6% 
 Very preterm (28 – < 32) 1.0% 0.9% 1.5% 0.8% 
 Moderately preterm (32 – <37) 7.9% 8.0% 9.7% 7.8% 
 Term (37+) 90.7% 90.5% 88.5% 90.9% 
*p < 0.10; **p < 0.05; ***p < 0.001 
aFor infants born after completing 37 weeks of gestation; N = 1,807 and 7,210 for NAA present and absent respectively; N = 1,367 and 
7,650 for asthma present and absent respectively 
bBirth weight less than 2 standard deviations from the sex – and gestational age – specific mean  
 
47 
 
 
Table 10: Maternal Characteristics across NAA type 
Characteristic Allergic Rhinitsa Atopic Dermatitisa 
 Present Absent Present Absent 
 (N = 1,093) (N = 8,872) (N = 959) (N = 9,006) 
     
Asthma *** *** 
 Yes 21.2% 14.8% 10.4% 16.1% 
      
Mother’s race *** *** 
 White non – Hispanic  52.3% 45.5% 42.4% 46.7% 
 Black non – Hispanic  44.7% 45.9% 52.9% 45.0% 
 Hispanic 2.6% 7.6% 4.0% 7.3% 
 Other 0.4% 1.1% 0.7% 1.0% 
aEach condition was considered separately 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
 
 
 
Table 11: Study Outcomes across NAA Type 
Characteristic Allergic Rhinitsa Atopic Dermatitisa 
 Present Absent Present Absent 
 (N = 1,093) (N = 8,872) (N = 959) (N = 9,006) 
     
Low birth weightb 4.4% 4.6% 4.4% 4.4% 
      
SGAc 2.3% 2.0% 1.9% 2.0% 
      
Preterm birth 9.3% 9.5% 9.4% 9.5% 
aEach condition was considered separately 
bFor infants born after completing 37 weeks of gestation; N = 991 and 8,026 for AR present and 
absent respectively; N = 869 and 8,148 for AD present and absent respectively 
cBirth weight less than 2 standard deviations from the sex – and gestational age – specific mean 
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Table 12: Study Outcomes by Atopy Types and Combinations 
 
Outcome Asthma NAA Present NAA Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 1,545) (N = 8,420) (N = 309) (N = 1,684) (N = 1,236) (N = 6,736) 
       
LBWa 4.9% 4.3% 4.7% 4.2% 4.9% 4.3% 
       
SGAb 2.4% 2.0% 1.6% 2.0% 2.6% 2.0% 
       
PTB 11.5% 9.1% ** 11.4% 9.0% 11.6% 9.2% ** 
aFor infants born after completing 37 weeks of gestation; N = 1,367 and 7,650 for Asthma present 
and absent respectively; N = 274 and 1,533 for Asthma present and absent respectively among 
mothers with NAA; N = 1,093 and 6,117 for Asthma present and absent respectively among 
mothers without NAA. 
bBirth weight less than 2 standard deviations from the sex – and gestational age – specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 13: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted 
Relative Risk (RRA) of Low Birth Weight among infants born after completing 37 weeks of 
gestation (N = 9,017) 
 
Outcome – LBW  RRC (95% CI)
a RRA (95% CI)
a 
    
NAA   
 No 1.00 [reference] 1.00 [reference] 
 Yes 0.97 (0.75 – 1.24) 0.96 (0.75 – 1.23) 
Asthma   
 No 1.00 [reference] 1.00 [reference] 
 Yes 1.15 (0.88 – 1.45) 1.05 (0.80 – 1.36) 
Infant sex   
 Male 1.00 [reference] 1.00 [reference] 
 Female 1.43 (1.17 – 1.74) *** 1.43 (1.17 – 1.74) *** 
    
Mother's age 1.00 (0.95 – 1.06) 1.01 (0.96 – 1.07) 
    
Race/Ethnicity   
 WNH 1.00 [reference] 1.00 [reference] 
 BNH 2.02 (1.63 – 2.51) *** 2.31 (1.84 – 2.90) *** 
 HISP 1.02 (0.63 – 1.63 1.18 (0.73 – 1.91) 
 OTHER 2.57 (1.20 – 2.50) ** 2.71 (1.26 – 5.82) ** 
Smoked during pregnancy   
 No 1.00 [reference] 1.00 [reference] 
 Yes 1.35 (1.05 – 1.74) ** 1.82 (1.39 – 2.37) *** 
Gestational diabetes   
 No 1.00 [reference] 1.00 [reference] 
 Yes 0.91 (0.50 – 1.66) 0.85 (0.47 – 1.56) 
Pre–pregnancy hypertension   
 No 1.00 [reference] 1.00 [reference] 
  Yes 1.58 (0.84 – 2.96) 1.37 (0.73 – 2.57) 
* p < 0.10; ** p < 0.05; *** p < 0.001 
a 95% Confidence Interval 
In a model adjusting for other predictors RRA & 95% confidence interval for the NAA – Asthma 
interaction 1.02 (0.53 – 1.99) 
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Table 14: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted 
Relative Risk (RRA) of Small for Gestational Age (N = 9,965) 
 
Outcome – SGA RRC (95% CI)
a RRA (95% CI)
a 
   
NAA   
 No 1.00 [reference] 1.00 [reference] 
 Yes 0.97 (0.67 – 1.36) 0.94 (0.66 – 1.34) 
Asthma   
 No 1.00 [reference] 1.00 [reference] 
 Yes 1.22 (0.85 – 1.74) 1.11 (0.78 – 1.59) 
Infant sex   
 Male 1.00 [reference] 1.00 [reference] 
 Female 0.94 (0.72 – 1.25) 0.95 (0.72 – 1.25) 
    
Mother's age 1.07 (0.99 – 1.15) * 1.06 (0.99 – 1.15) * 
    
Race/Ethnicity   
 WNH 1.00 [reference] 1.00 [reference] 
 BNH 1.57 (1.17 – 2.10) **  1.85 (1.35 – 2.52) *** 
 HISP 0.80 (0.40 – 1.61) 0.98 (0.48 – 1.97) 
 OTHER 2.49 (0.91 – 6.81) * 2.69 (0.98 – 7.39) * 
Smoked during pregnancy   
 No 1.00 [reference] 1.00 [reference] 
 Yes 1.71 (1.22 – 2.37) ** 2.09 (1.47 – 2.97) *** 
Gestational diabetes   
 No 1.00 [reference] 1.00 [reference] 
 Yes 1.21 (0.60 – 2.45) 1.04 (0.51 – 2.13) 
Pre–pregnancy hypertension   
 No 1.00 [reference] 1.00 [reference] 
  Yes 2.79 (1.52 – 5.13) ** 2.45 (1.32 – 4.53) ** 
* p < 0.10; ** p < 0.05; *** p < 0.001 
a 95% Confidence Interval 
In a model adjusting for other predictors RRA & 95% confidence interval for the NAA – Asthma 
interaction 0.63 (0.23 – 1.76) 
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Table 15: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted 
Relative Risk (RRA) of Preterm Birth (N = 9,965) 
 
Outcome – PTB RRC (95% CI)
a RRA (95% CI)
a 
     
NAA    
 No 1.00 [reference] 1.00 [reference] 
 Yes 0.98 (0.84 – 1.15) 0.95 (0.81 – 1.12) 
Asthma    
 No 1.00 [reference] 1.00 [reference] 
 Yes 1.26 (1.07 – 1.49) ** 1.20 (1.02 – 1.41) ** 
Infant sex    
 Male 1.00 [reference] 1.00 [reference] 
 Female 0.98 (0.86 – 1.11) 0.97 (0.85 – 1.10) 
     
Mother's age 1.01 (0.98 – 1.05) 1.00 (0.97 – 1.04) 
     
Race/Ethnicity    
 WNH 1.00 [reference] 1.00 [reference] 
 BNH 1.35 (1.18 – 1.54) *** 1.32 (1.15 – 1.51) *** 
 HISP 0.58 (0.41 – 0.82) ** 0.59 (0.41 – 0.84) ** 
 OTHER 0.95 (0.47 – 1.92) 0.96 (0.48 – 1.94) 
Smoked during pregnancy    
 No 1.00 [reference] 1.00 [reference] 
 Yes 0.98 (0.81 – 1.17) 1.04 (0.86 – 1.25) 
Gestational diabetes    
 No 1.00 [reference] 1.00 [reference] 
 Yes 1.74 (1.32 – 2.29) *** 1.61 (1.22 – 2.13) ** 
Pre–pregnancy hypertension    
 No 1.00 [reference] 1.00 [reference] 
  Yes 3.00 (2.28 – 3.94) *** 2.68 (2.03 – 3.53) *** 
* p < 0.10; ** p < 0.05; *** p < 0.001 
a 95% Confidence Interval 
In a model adjusting for other predictors RRA & 95% confidence interval for the NAA – Asthma 
interaction 0.98 (0.65 – 1.48) 
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Table 16: Summary of Atopy by Maternal Race/Ethnicity 
 WNH  
(N = 4,607) 
BNH 
(N = 4,556) 
Exposure n (%) n (%) 
   
Non – Asthmatic Atopy 960 (20.8) 957 (21.0) 
   
Allergic Rhinitis (AR) ** 572 (12.4) 489 (10.7) 
   
Atopic Dermatitis (AD) *** 407 (8.8) 507 (11.1) 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
Table 17: Summary of Study Outcomes by Maternal Race/Ethnicity 
Characteristic WNH (N = 4,607) BNH (N = 4,556) 
n (%) n (%) 
   
Low birth weighta *** 125 (3.0) 242 (6.0) 
    
Small for gestational ageb ** 74 (1.6) 115 (2.5) 
    
Birth weight (grams) ***   
 Extremely lbw (< 1,000) 18 (0.4) 39 (0.9) 
 Very lbw (1,000 – 1,499) 38 (0.8) 53 (1.2) 
 Moderately lbw (1,500 – 2,499) 288 (6.3) 527 (11.6) 
 Normal bw (2,500 – 3,999) 3,966 (86.1) 3,803 (83.5) 
 High bw (4,000+) 297 (6.5) 134 (2.9) 
    
Preterm birth *** 387 (8.4) 515 (11.3) 
    
Gestational age at birth (weeks) ***   
 Extremely preterm (< 28) 18 (0.4) 37 (0.8) 
 Very preterm (28 – < 32) 35 (0.8) 55 (1.2) 
 Moderately preterm (32 – <37) 334 (7.3) 423 (9.3) 
 Term (37+) 4,220 (91.6) 4,041 (88.7) 
aFor infants born after completing 37 weeks of gestation; N = 4,220 and 4,041 respectively 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean  
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 18: Study Outcomes by NAA by Maternal Race/Ethnicity 
Characteristic WNH BNH 
 NAA+ NAA– NAA+ NAA– 
 (N = 960) (N = 3,647) (N = 957) (N = 3,599) 
     
Low birth weighta 2.8% 3.0% 5.7% 6.1% 
      
Small for gestational ageb 1.6% 1.6% 2.2% 2.6% 
      
Birth weight (grams)     
 Extremely lbw (< 1,000) 0.2% 0.4% 0.7% 0.9% 
 Very lbw (1,000 – 1,499) 0.4% 0.9% 0.9% 1.2% 
 Moderately lbw (1,500 – 2,499) 6.2% 6.3% 11.1% 11.7% 
 Normal bw (2,500 – 3,999) 86.6% 86.0% 83.8% 83.4% 
 High bw (4,000+) 6.7% 6.4% 3.5% 2.8% 
      
Preterm birth 7.7% 8.6% 11.3% 11.3% 
      
Gestational age at birth (weeks)     
 Extremely preterm (< 28) 0.2% 0.4% 0.6% 0.9% 
 Very preterm (28 – < 32) 0.7% 0.8% 1.4% 1.2% 
 Moderately preterm (32 – <37) 6.8% 7.4% 9.3% 9.3% 
 Term (37+) 92.3% 91.4% 88.7% 88.7% 
aFor infants born after completing 37 weeks of gestation; N = 886 and 3,334 for NAA present and 
absent respectively among WNH. N = 849 and 3,192 for NAA present and absent respectively 
among BNH. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 19: Study Outcomes by Atopy Types and Combinations among WNH women 
Outcome Asthma NAA Present NAA Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 684) (N = 3,923) (N = 127) (N = 833) (N = 557) (N = 3,090) 
       
LBWa 3.9% 2.8%  4.4% 2.6% 3.8% 2.9%  
       
SGAb 2.3% 1.5% *  3.2% 1.3% 2.2% 1.5% 
       
PTB 10.1% 8.1% * 10.2% 7.3% 10.1% 8.3% 
aFor infants born after completing 37 weeks of gestation; N = 615 and 3,605 for Asthma present 
and absent respectively; N = 114 and 772 for Asthma present and absent respectively among 
mothers with NAA; N = 501 and 2,833 for Asthma present and absent respectively among 
mothers without NAA. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
 
Table 20: Study Outcomes by Atopy Types and Combinations among BNH women 
Outcome Asthma NAA Present NAA Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 796) (N = 3,760) (N = 166) (N = 791) (N = 630) (N = 2,969) 
       
LBWa 5.9% 6.0% 4.8% 5.8% 6.2% 6.1% 
       
SGAb 2.5% 2.5% 0.6% 2.5% 3.0% 2.5% 
       
PTB 13.0% 11.0% 12.1% 11.1% 13.2% 11.0% 
aFor infants born after completing 37 weeks of gestation; N = 693 and 3,348 for Asthma present 
and absent respectively; N = 146 and 703 for Asthma present and absent respectively among 
mothers with NAA; N = 547 and 2,645 for Asthma present and absent respectively among 
mothers without NAA. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 21: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted Relative Risk (RRA) of Low Birth Weight 
among infants born after completing 37 weeks of gestation for WNH women (N = 4,220) and BNH women (N = 4,046) 
 
Outcome – LBW WNH BNH 
RRC (95% CI)
a RRA (95% CI)
a RRC (95% CI)
a RRA (95% CI)
a 
NAA      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 0.94 (0.61 – 1.46) 0.95 (0.61 – 1.48) 0.93 (0.68 – 1.28) 0.94 (0.68 – 1.28) 
Asthma      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 1.39 (0.89 – 2.17) 1.29 (0.83 – 2.02) 0.99 (0.70 – 1.38) 0.96 (0.68 – 1.34) 
Infant sex      
 Male 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Female 1.02 (0.72 – 1.45) 1.01 (0.71 – 1.44) 1.66 (1.28 – 2.15) *** 1.66 (1.28 – 2.16) *** 
      
Mother's age 0.99 (0.89 – 1.09) 0.99 (0.90 – 1.09) 1.00 (0.93 – 1.08) 1.00 (0.94 – 1.08) 
Smoked during pregnancy      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 2.07 (1.45 – 2.96) *** 2.03 (1.42 – 2.90) *** 1.35 (0.85 – 2.16) 1.36 (0.85 – 2.17) 
Gestational diabetes      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 0.56 (0.14 – 2.27) 0.55 (0.13 – 2.23) 1.00 (0.50 – 2.03) 1.00 (0.49 – 2.02) 
Pre–pregnancy hypertension      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
  Yes 1.58 (0.39 – 6.39) 1.69 (0.41 – 6.86) 1.40 (0.69 – 2.84) 1.38 (0.68 – 2.80) 
* p < 0.10; ** p < 0.05; *** p < 0.001 
a 95% Confidence Interval 
In a model adjusting for other predictors RRA for NAA–Asthma interaction among WNH 1.40 (0.46 – 4.21) 
In a model adjusting for other predictors RRA for NAA–Asthma interaction among BNH 0.79 (0.33 – 1.91)
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Table 22: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted Relative Risk (RRA) of Small for 
Gestational Age among WNH women (N = 4,607) and BNH women (4556) 
 
Outcome – SGA WNH BNH 
RRC (95% CI)
a RRA (95% CI)
a RRC (95% CI)
a RRA (95% CI)
a 
NAA      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 0.97 (0.55 – 1.70) 0.97 (0.55 – 1.72) 0.84 (0.52 – 1.35) 0.84 (0.52 – 1.35) 
Asthma      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 1.58 (0.91 – 2.75) 1.47 (0.84 – 2.57) 0.99 (0.61 – 1.61) 0.96 (0.60 – 1.56) 
Infant sex      
 Male 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Female 0.52 (0.32 – 0.85) ** 0.51 (0.32 – 0.84) ** 1.26 (0.88 – 1.83) 1.28 (0.89 – 1.86) 
       
Mother's age 1.01 (0.89 – 1.14) 0.99 (0.88 – 1.13) 1.11 (1.00 – 1.22) ** 1.10 (0.99 – 1.21) * 
Smoked during pregnancy      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 2.28 (1.44 – 3.62) *** 2.22 (1.40 – 3.52) ** 1.66 (0.89 – 3.08) 1.61 (0.86 – 2.99) 
Gestational diabetes      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 0.45 (0.06 – 3.22) 0.38 (0.05 – 2.73) 1.71 (0.80 – 3.68) 1.53 (0.71 – 3.32) 
Pre–pregnancy hypertension      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
  Yes 4.06 (1.48 – 11.11) ** 4.09 (1.47 – 11.34) ** 2.24 (1.04 – 4.81) ** 2.03 (0.94 – 4.39) * 
* p < 0.10; ** p < 0.05; *** p < 0.001 
a 95% Confidence Interval 
In a model adjusting for other predictors RRA for NAA–Asthma interaction among WNH women 1.87 (0.50 – 6.93) 
In a model adjusting for other predictors RRA for NAA–Asthma interaction among BNH women 0.19 (0.02 – 1.54)
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Table 23: Poisson Regression Models Displaying the Crude Relative Risk (RRC) and Adjusted Relative Risk (RRA) of Preterm Birth 
among WNH women (N = 4,607) and BNH women (4,556) 
 
Outcome – PTB WNH BNH 
RRC (95% CI)
a RRA (95% CI)
a RRC (95% CI)
a RRA (95% CI)
a 
NAA      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 0.90 (0.70 – 1.16) 0.90 (0.68 – 1.13) 1.00 (0.81 – 1.23) 1.00 (0.81 – 1.24) 
Asthma      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 1.24 (0.96 – 1.61) * 1.20 (0.92 – 1.56) 1.18 (0.95 – 1.46) 1.17 (0.94 – 1.45) 
Infant sex      
 Male 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Female 0.87 (0.71 – 1.06) 0.87 (0.71 – 1.06) 1.07 (0.90 – 1.28) 1.07 (0.90 – 1.27) 
       
Mother's age 1.04 (0.98 – 1.09) 1.02 (0.97 – 1.08) 1.01 (0.96 – 1.06) 1.00 (0.95 – 1.05) 
Smoked during pregnancy      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 1.03 (0.82 – 1.30) 1.01 (0.80 – 1.27) 1.14 (0.81 – 1.61) 1.11 (0.79 – 1.56) 
Gestational diabetes      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
 Yes 1.59 (0.99 – 2.55) * 1.36 (0.84 – 2.21) 1.81 (1.27 – 2.57) ** 1.76 (1.24 – 2.52) ** 
Pre–pregnancy hypertension      
 No 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 
  Yes 4.07 (2.62 – 6.32) *** 3.81 (2.43 – 5.96) *** 2.29 (1.59 – 3.27) *** 2.22 (1.55 – 3.18) *** 
* p < 0.10; ** p < 0.05; *** p < 0.001 
a 95% Confidence Interval 
In a model adjusting for other predictors RRA for NAA–Asthma interaction among WNH women 1.11 (0.57 – 2.16) 
In a model adjusting for other predictors RRA for NAA–Asthma interaction among BNH women 0.85 (0.49 – 1.47)
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Table 24: Maternal Demographic and Clinical Characteristics by Control Category 
Characteristic SC 
(N = 7,972) 
RC 
(N = 55,685) 
    
Sex   
 Female 48.4% 49.1% 
 Male 51.6% 50.9% 
    
Mother’s race***   
 White non – Hispanic 45.8% 46.2% 
 Black non – Hispanic 45.2% 43.5% 
 Hispanic 7.9% 9.1% 
 Other 1.1% 1.2% 
    
Smoking prior to pregnancy 18.8% 18.8% 
    
Smoking during pregnancy 14.6% 14.4% 
    
Pre–pregnancy diabetes 0.7% 0.7% 
    
Gestational diabetes 3.3% 3.3% 
   
Pre–pregnancy hypertension** 2.0% 1.7% 
   
Asthma*** 15.5% 2.7% 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
Table 25: Study Outcomes by Control Category 
Characteristic SC 
(N = 7,972) 
RC 
(N = 55,685) 
   
Low birth weighta 4.4% 4.3% 
   
SGAb 2.0% 2.0% 
    
Preterm birth 9.5% 9.2% 
aFor infants born after completing 37 weeks of gestation; N = 7,210 and 50,559 for SC and RC 
respectively 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Figure 1: Percent of Mothers with a Non – Asthmatic Atopy by Infant Birth Weight  
p < 0.001 for increasing trend 
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Figure 2: Percent of Mothers with Asthma by Infant Birth Weight  
p < 0.001 for decreasing trend 
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Figure 3: Percent of Mothers with a Non – Asthmatic Atopy by Infant Gestational Age at Birth 
p < 0.001 for increasing trend  
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Figure 4: Percent of Mothers with a Non – Asthmatic Atopy by Fetuses at Risk for Gestational Age 
at Birth 
p < 0.001 for overall increasing trend 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks 
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Figure 5: Percent of Mothers with Asthma by Infant Gestational Age at Birth of Offspring 
p < 0.001 for decreasing trend 
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Figure 6: Percent of Mothers with Asthma by Fetuses at Risk for Gestational Age at Birth 
p < 0.001 for overall increasing trend 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks 
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Figure 7: Percent of Mothers with Non – Asthmatic Atopy by Infant Birth Weight by 
Race/Ethnicity 
p < 0.001 for increasing trend among WNH mothers 
p < 0.001 for increasing trend among BNH mothers 
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Figure 8: Percent of Mothers with Asthma by Infant Birth Weight by Race/Ethnicity 
p < 0.001 for decreasing trend among WNH mothers 
p < 0.001 for decreasing trend among BNH mothers 
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Figure 9: Percent of Mothers with Non – Asthmatic Atopy by Infant Gestational Age at Birth by 
Race/Ethnicity 
p < 0.001 for increasing trend among WNH mothers 
p < 0.001 for increasing trend among BNH mothers 
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Figure 10: Percent of Mothers with a Non – Asthmatic Atopy by Fetuses at Risk for Gestational 
Age at Birth by Race/Ethnicity 
p < 0.001 for overall increasing trend among WNH mothers 
p < 0.001 for overall increasing trend among BNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers 
 
 
 
 
 
 
 
 
0
1
0
2
0
3
0
25 30 35 40 45 25 30 35 40 45
White Non - Hispanic Mothers Black Non - Hispanic Mothers
P
e
rc
e
n
t
Gestational Age at Birth/Weeks
 69 
 
 
 
Figure 11: Percent of Mothers with Asthma by Infant Gestational Age at Birth by Race/Ethnicity 
p < 0.001 for decreasing trend among WNH mothers 
p < 0.001 for decreasing trend among BNH mothers 
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Figure 12: Percent of Mothers with Asthma by Fetuses at Risk for Gestational Age at Birth by 
Race/Ethnicity 
p < 0.001 for overall increasing trend among WNH mothers 
p < 0.001 for overall increasing trend among BNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers 
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CHAPTER FIVE: DISCUSSION 
 
5.1 FINDINGS CONSISTENT WITH THE LITERATURE 
 
5.1.1 MAJOR FINDINGS CONSISTENT WITH THE LITERATURE 
 The statistical models used in this study quantified a protective but not statistically 
significant, effect of non – asthmatic atopy (NAA) on all study outcomes. When considering the 
conditions separately, both allergic rhinitis (AR) and atopic dermatitis (AD) were estimated to have 
mildly protective effects (RRA = 0.91 and 0.98 resp.) on PTB. These estimates were not statistically 
significant. In their study Trønnes et al found AR and AD to be protective against PTB (RR = 0.84 
and 0.90 respectively) (Trønnes et al., 2014). This study found a higher prevalence of AR among 
WNH mothers compared to BNH mothers (12.4% vs. 10.7%, p < 0.05) and a higher prevalence of 
AD among BNH mothers compared to WNH mothers (11.1% vs. 8.8%, p < 0.001). This is 
consistent with previous research. Hjern et al found that AR was more prevalent among persons of 
European and Australian descent (Hjern et al., 2000). While Williams et al found that AD is more 
prevalent among persons of African descent (Williams et al., 1999). 
 This study found similar trends as did Savilahti et al. In their 2004 study, Savilhati et al 
found that mothers of very low birth weight infants had significantly less atopy than mothers of full 
term infants (AR; 27% vs. 34% resp., AD; 29% vs. 33% resp.) (Savilahti et al., 2004). This study also 
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found that the mothers of very low birth weight infants had less atopy than the mothers of full term 
infants (AR; 8.72% vs. 11.00% resp., AD; 6.76% vs. 9.64% resp.), however these results were not 
statistically significant. This study did however find a statistically significant increasing trend of the 
percentage of mothers with non – asthmatic atopy across infant birth weight. Mothers with heavier 
babies at birth had higher percentages of NAA. This study also found a similar trend across infant 
gestational ages at birth. Mothers who gave birth later had higher percentages with non – asthmatic 
atopy. And further the percentages of mothers with NAA dropped sharply after 40 weeks of 
gestation. 
 The statistical models used in this study estimated that asthma increased the risk each study 
outcome; LBW (RRA = 1.05; p > 0.05), SGA (RRA = 1.11; p > 0.05), and PTB (RRA = 1.20; p = 0.03). 
This increased risk of asthma on PTB was comparable to the effect found by both Murphy et al in 
their 2011 study (RR = 1.41) (V. Murphy et al., 2011) and Trønnes et al in their 2014 study (RR = 
1.15) (Trønnes et al., 2014). The increased risk that asthma has SGA, was also comparable to the 
effect found by Murphy (RR = 1.22) (V. Murphy et al., 2011). A statistically significant decreasing 
trend of the percentages of mothers with asthma across infant birth weight was also detected. There 
was a similar decreasing trend across infant gestational ages at birth. Mothers who gave birth earlier 
had higher percentages with asthma. See Appendix A for a summary findings consistent with the 
literature.   
 
5.1.2 OTHER FINDINGS CONSISTENT WITH THE LITERATURE 
 The proportion of infants in this study that were born with low birth weight was 10.1%. 
This proportion is comparable to the 2014 State average of 9.7% (CDC, 2015a), but different from 
 73 
 
the 2014 national rate of 8.0% (CDC, 2015a). Among infants who were born after completing at 
least 37 weeks of gestation, the proportion born with low birth weight was 4.4%. 
 This study found that approximately 20% of participants smoked before pregnancy and that 
approximately 15% continued to smoke during pregnancy. These estimates are consistent with 
percentages of between 12% to 22% of women and girls smoking that is found in the literature 
(CDC, 2004) and further that between 18% and 25% quit once they become pregnant (CDC, 2004). 
It is well documented that smoking during pregnancy increases the risk of adverse pregnancy 
outcomes including LBW, SGA and PTB (SILVERMAN, 1977). This study found that smoking 
during pregnancy increased the risks of LBW and SGA. These estimated increases in risk remained 
statistically significant among WNH women only when the data was analyzed by maternal 
race/ethnicity. This could be due to the higher prevalence of smoking during pregnancy found 
among WNH women compared to BNH women (25% vs. 6%).  
 Chronic diseases such as diabetes and pre – pregnancy hypertension were found to increase 
the risks of SGA and PTB, while pre – pregnancy hypertension was found to also increase the risk 
of LBW. These findings are consistent with the literature indicating that these types of chronic 
diseases in the mother put them at increased risk for adverse pregnancy outcomes (Casson et al., 
1997; Yogev & Visser, 2009). In addition to this, this study found that pre – pregnancy hypertension 
was associated with a statistically significant increase in the risks of SGA and PTB among both WNH 
and BNH women. While gestational diabetes was found to increase the risk of PTB and this 
increased risk remained statistically significant among BNH women only when the data was analyzed 
by maternal race/ethnicity. See Appendix A for a summary of findings consistent with the literature. 
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5.2 FINDINGS WHICH DIFFER FROM THE LITERATURE 
  
5.2.1 MAJOR FINDINGS WHICH DIFFER FROM THE LITERATURE 
 The estimated prevalence of atopy (allergic rhinitis, atopic dermatitis and asthma) found 
among this population is 7.20% which is approximately one–third the estimates given in the 
literature of between 20 and 25% of the general adult population aged 16 to 65 years (Franzese, 
2011). This estimate is in keeping with the fact that this study was restricted to women between the 
ages of 19 & 25. In addition to this allergic rhinitis is often both underdiagnosed and misdiagnosed 
(Greiner et al., 2012). The prevalence of non – asthmatic atopy in this population is estimated to be 
3.0%. This estimate is much lower than the estimated found in the literature (Franzese, 2011; Ruby 
Pawankar et al., 2012). 
 The estimated prevalence of asthma found in this study was 4.6%. This is very different from 
the 7.0% of adults estimated by the CDC (CDC, 2013a) and the prevalence of between 8% and 
13% worldwide found by Murphy et al (V. E. Murphy & Gibson, 2011). This could also be due to 
the fact that only a portion of all adults would be represented in the study cohort; i.e. mothers 
between the ages of 19 and 25 years, and, further, asthma prevalence rates for this specific age group 
are not available. 
 This study found that approximately 15.5% of persons with NAA also have asthma. This is 
lower than the estimated 40% in the literature (Kim et al., 2008; Ruby Pawankar, 2002). This 
suggests that at least 60% of women who do not have asthma with NAA may have the benefit of 
reduced risk of adverse pregnancy outcomes. 
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 Also found was the fact that 10.1% of women who had asthma also had another atopy. This 
is markedly less than estimates ranging between 30% and 80% (Kim et al., 2008) in the literature. 
Health professionals should, therefore, seek to identify other forms of atopy that may be diagnosable 
at the same time as asthma, since the findings of this study suggest that the presence of NAA along 
with asthma may reduce the negative effect that asthma has on pregnancy outcomes for some women 
and exacerbate this effect for others. 
 Very interestingly, this study study found that asthma increased the risk of LBW among 
WNH women and not BNH women (RRA = 1.29 and 0.96 resp.), while Aly et al found the reverse 
trend that asthma increased the odds of LBW among BNH women and not WNH women (OR = 
1.7 and 0.99 resp.). See Appendix B for a summary of findings which differ from the literature. 
 
5.2.2 OTHER FINDINGS WHICH DIFFER FROM THE LITERATURE 
 The proportion of infants in this study that were born preterm was 9.5% which is different 
and less than the estimated State prevalence of 13.75% (CDC, 2015a) and the estimated national 
prevalence of 11.4% (CDC, 2015a). This discrepancy in the prevalence of preterm birth can be 
explained by the fact that mothers studied were between the ages of 19 and 25 years and the 
prevalence of preterm birth tends to be higher among older women (CDC, 2014b). This discrepancy 
could also be due to the fact that the births examined in this study occurred over a 10 – year period 
and further only included a subset of all births i.e. mother’s first live birth. See Appendix B for a 
summary of findings which differ from the literature. 
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5.3 STUDY STRENGTHS 
 This study had the strength of drawing information from two large databases producing 
more than 60,000 records. The Medicaid database has the primary purpose of being used 
administratively and not for research and as such is less likely to contain systematic biases in 
diagnosis codes. The quality of the data was good within variables used to calculate study outcomes, 
LBW, SGA and PTB being complete i.e. less than 1% of data missing. Further, complete 
information was available for 97.5% of all maternal records found. Data on other characteristics 
such as maternal age, race/ethnicity, smoking, diabetes and hypertension was also complete with 
less than 1% of data missing.  
The major findings of this study suggest that the data are internally valid. This is evidenced 
by the fact that the investigated condition; NAA affects all outcomes in a similar way. This study also 
found that AR is more prevalent among WNH and AD is more prevalent among BNH, both these 
findings are consistent with the literature. It can also be inferred that the data accuracy was good as 
findings about other factors that have been previously documented such as, smoking, hypertension 
and diabetes are consistent with current literature (see Appendix A). The findings in this study are 
consistent with the literature that maternal smoking increases the risk of infants being born LBW 
and SGA. This is a phenomenon which has persisted in the literature since 1977. It has also been 
relatively well documented over the past 20 years that chronic conditions in the mother such as 
diabetes and hypertension are associated with increased risk of adverse pregnancy outcomes such as 
LBW, SGA and PTB. The findings of this study are consistent with that. The data used in this study 
also produced statistics consistent with estimates from 2004 on the percent of women who smoke 
as well as the percent who smoke during pregnancy (see Appendix A). These data also displayed 
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similar trends as previously published data from 2004 on how atopy was likely to be associated with 
birth weight and fetal development. Analyses also confirmed what previous research had found with 
respect to asthma being associated with an increased risk of PTB. The estimated State prevalence of 
LBW was also consistent with the most recent CDC estimate of same (see Appendix A). These 
findings that are both in agreement with data from varying time periods i.e. 1970s, 1990s, 2000s, 
and the fact that risk estimates are consistent with previously published findings, provide evidence 
that the data used are accurate and contain no systematic bias that would otherwise explain the 
results. This further suggests that information on NAA is also credible.  
Study investigators are also confident that no systematic bias was introduced during data 
selection and data cleaning. The distributions of study outcomes and other characteristics, with the 
exception of pre – pregnancy hypertension, remained consistent when examining the controls who 
were selected for the primary analysis (selected controls, SC) and comparing them to the controls 
who were not selected for the primary analysis (remaining controls, RC). There was a slightly higher 
rate of pre – pregnancy hypertension in SC when compared to RC (2.0% vs. 1.7%, p < 0.05). The 
magnitude of this difference is very slight and the distribution of pre – pregnancy hypertension was 
not statistically different between the NAA group and the SC group. In addition to this, pre – 
pregnancy hypertension was one of the conditions controlled for in the statistical models that were 
used to estimate the risk of each outcome.  Again this provides evidence that the differences 
estimated were in fact due to NAA status.  
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5.4 FINDINGS RELATED TO LIMITATIONS 
 There were findings that could not be verified as data on the specific age group examined in 
this study are not available. The proportion of women with diabetes in this study was estimated to 
be 0.7%. This is an acceptable estimate of the proportion of women with diabetes who are between 
the 19 and 25 years, as the prevalence of diabetes among women under the age of 44 years was 
estimated to be 1.5% in 2014 (CDC, 2015b). This study estimated that the proportion of women 
with gestational diabetes was approximately 3.3%. This is also a plausible estimate as the prevalence 
of gestational diabetes among all pregnant women was estimated to be 9.2% in 2010 (DeSisto, 2014). 
Within this study population, the proportion of women with hypertension was 2.0%. Again, while 
not verifiable this estimate is reasonable given that it was estimated that 6.8% of women between 
the ages of 20 and 34 years have hypertension (CDC, 2015c). See Appendix C for findings related 
to limitations.  
 In addition to information that was known but could not be verified due to unavailable age 
– specific data, there was information that was not known, and, therefore, could not be controlled 
for.  There was no information on the severity of each atopic disease. Likewise, there was no specific 
information on timing of symptom onset. I.e. did mothers experience symptoms in particular 
trimesters of pregnancy or throughout their entire pregnancies? The only available information on 
diagnosis is that it was at least 1 year prior to pregnancy. This study was not able to assess and control 
for medication taken by the mother to treat NAA or study outcomes. In addition, this study could 
not control for geographical effects including: place of residence, duration at residence, place of 
birth; which may affect the severity of atopic conditions. 
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5.5 IMPLICATIONS FOR PUBLIC HEALTH 
 The results of this study indicate that there is a need for increased monitoring and 
surveillance of atopic conditions, not just asthma, but also allergic rhinitis and atopic dermatitis. 
Many of the findings are new, and, there is no information that has been published about these 
effects. This study found that NAA reduces the risk of LBW and SGA among WNH women (RRA 
= 0.95 and 0.97 resp.). NAA was also found to reduce the risk of LBW and SGA among BNH 
women (RRA = 0.94 and 0.84 resp.). NAA was not found to affect the risk of PTB among BNH 
women (RRA = 1.0).   
The findings of this study also suggest that the interaction between atopic conditions may 
differ according to race/ethnicity. This study found that the interaction between asthma and other 
atopic conditions increased the risk of LBW, SGA and PTB among WNH women (RRA = 1.40, 1.87 
and 1.11 resp.). However, this same interaction was found to reduce the risk of LBW, SGA and PTB 
among BNH (RRA = 0.79, 0.19 and 0.85 resp.). This apparent discrepancy in effect could be due to 
treatment which, as previously mentioned this study was unable to assess. The prevalence of each 
study outcome was higher among BNH mothers when compared to WNH mothers. It is, therefore, 
possible that a BNH mother diagnosed with more than one atopy, was treated with medication or, 
some other intervention for at least one atopy, or another type of intervention that would affect the 
study outcomes, was implemented. Murphy et al found that asthma medication was effective in 
reducing the risk of LBW  (V. Murphy et al., 2011) and Bakhireva et al found that PTB was associated 
with poor asthma symptom control and not just a diagnosis of asthma (Bakhireva et al., 2008). This 
suggests that the way in which asthma along with NAA modified the risk of each study outcome, 
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was different for WNH women when compared to BNH women who had asthma along with another 
atopy. It is plausible that the interactions of different types of atopy would affect WNH women and 
BNH women differently due to biological differences across race/ethnicity. This has been found to 
be the case with smoking cigarettes and the subsequent metabolism of cotinine. Researchers have 
found that there are higher levels of cotinine detected in the blood of blacks for each cigarette 
smoked when compared to whites (Perez-Stable, Herrera, Jacob III, & Benowitz, 1998). 
It is also possible that atopic conditions may interact with other health conditions. This study 
suggests that there is an underlying mechanism between atopy and pregnancy outcome, which may 
vary by race/ethnicity and access to health care. This study estimated a low prevalence of NAA 
although previous research suggests that the prevalence of NAAA is much higher and increasing 
among the general population, and, hence, women. This low prevalence can be explained by the fact 
that atopy, particularly AR and AD are not screened for, and, hence, not actively managed unless 
the patient is manifesting symptoms. If the presence of NAA could provide protection against the 
adverse pregnancy outcomes studied here, then a diagnosis of NAA should be taken into account 
when assessing a woman’s risk of an adverse outcome. 
 It is well established that uncontrolled asthma increases the risk of adverse pregnancy 
outcomes. The protective effect of other atopic conditions may be overlooked because asthma is also 
present, and more actively managed. While it is possible to have single atopic conditions, it has been 
hypothesized that they are interrelated in such a way, that careful management of one condition is 
beneficial in reducing the symptoms of another (i.e. management of AR is essential to effective 
asthma control and vice versa). Further, current trends suggest that these conditions can develop or 
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manifest at any age, and therefore should not be overlooked in achieving optimal health care for 
patients. 
 
5.5.1 FUTURE DIRECTIONS 
It can be deduced that the maternal immune system is heavily involved in the successful 
completion of a pregnancy (Savilahti et al., 2004), and there may be several reasons for the apparent 
protective effect of NAA on pregnancy. Firstly, the proportion of mothers diagnosed with NAA is 
relatively low, supporting previous research that NAA, in particular AR is often underdiagnosed 
(Greiner et al., 2012). It is possible that mothers actually receiving such as diagnosis are the ones 
who are more severely affected, and, therefore, more actively seek out medical care. This leads to an 
increase in both preconception and prenatal care which have been shown to improve health 
outcomes for both the mother and child (Bhutta, Dean, Imam, & Lassi, 2011; Salihu, Myers, & 
August, 2012). However, the controls in this study would also have received a similar amount of 
preconception and prenatal care and so this still suggests that the benefits observed are in fact due 
to NAA providing protection against adverse pregnancy outcomes.  
Another possible explanation for the apparent protective effect is the biological process 
associated with these two immune responses. Both AR and AD are associated with a T – helper 2 
cell dominant humoral responses from the immune system (Savilahti et al., 2004; Trønnes et al., 
2014). This response is less associated with inflammation and more so with an increase in mucus 
production. Mucus production assists in removing pathogens that may prove harmful to the 
pregnancy. This shift in immune response is also beneficial for the pregnancy in avoiding fetal 
rejection that is more likely in a T – helper 1 cell dominant immune response (Warner, Jones, 
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Williams, & Warner, 1998). This has gone unnoticed for the most part mainly due to the fact that 
in many instances when persons have NAA they also have asthma, and the benefit of NAA is hidden 
behind the adverse effects of asthma.  
It is also plausible that persons diagnosed with allergies make lifestyle adjustments in order 
to avoid triggers which produce at the very least uncomfortable symptoms. These adjustments lead 
to an improved environment which includes the avoidance of pathogens that may be harmful to the 
pregnancy. This is, however, not the whole story as there is a lack of knowledge to the role that the 
external environment plays in allergic sensitization and the manifestation of associated symptoms. 
Persons who are exposed to pathogens early on in life such as having a pet or living on a farm, have 
been shown to suffer less from allergic disorders (Gordon, 2011). This protection however has been 
shown to not be lifelong, and may decrease as the exposure to the familiar pathogens decreases, 
making a person become more sensitive and prone to developing an allergic disorder (Douwes et al., 
2007; Eriksson et al., 2010). It is plausible that the immune system which now being idle, not having 
pathogens consistently to contend with; overreacts when it does come into contact with a previously 
very familiar pathogen. It stands ready so to speak to attack, leading to increased protection in the 
case of an expectant mother albeit accompanied by annoying and possibly uncomfortable symptoms.  
 In order to further explore the relationship between NAA and pregnancy outcomes and 
address some of the limitations of this study, it would be beneficial to enroll a prospective cohort of 
women expanding the age range of participants, where dates of diagnosis, severity of symptoms, 
Immunoglobulin E levels can be measured and timing of symptoms are known.  
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I would also like to explore the postulated allergic continuum. It has been hypothesized that 
there is an order to developing allergic responses with AD being the first stage, and asthma being 
the final. I would like to further investigate this in the population. 
 I would also like to explore how taking medication to treat the symptoms of NAA may affect 
fetal development and pregnancy outcomes. Research up to this point has not been able to address 
what would constitute best practices with regard to treating asthma during pregnancy, and, further, 
no studies have been conducted to evaluate how medication taken to treat allergic rhinitis or atopic 
dermatitis may affect pregnancy outcomes. In order to address this question it would be helpful to 
have access to patients’ pharmacologic data over time. This database would ideally contain both 
prescription medicines and those obtained over the counter. This would provide a means to not 
only investigate how treatments for NAA may affect the study results, but also, to adequately control 
for, and explain, the effects of other medications that a patient may be taking.  
 
5.6 CONCLUSION  
 The presence of NAA; AR and/or AD provides protection against adverse pregnancy 
outcomes such as low birth weight, small for gestational age and preterm birth. Until now their 
protective effect has not been recognized due to the fact that in many cases asthma is also often 
present. If asthma can be excluded in assessing maternal risk for adverse pregnancy outcomes, then 
the remaining atopic mothers have improved pregnancy outcomes. This is likely due to a positive 
influence of the T – helper 2 cell immune response to pathogens from the mother’s immune system 
and its interaction with the placenta/fetus.  
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Even among some women with asthma, the presence of NAA reduces the negative effect of 
asthma on pregnancy outcomes. 
This study also suggests that the mechanisms associated with an infant being born LBW, 
SGA or PTB include a pathway which can be explained by an active maternal immune system. Even 
among non – atopic mothers, immune system activity must include 2 stages during pregnancy. 
Firstly, the immune system is initially suppressed early on in the pregnancy to facilitate implantation 
and prevent rejection of the fetus; and secondly the immune system’s ability to convert from having 
T – helper 1 cell dominant responses to having T – helper 2 cell dominant responses to pathogens 
during pregnancy.  
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APPENDIX A: FINDINGS CONSISTENT WITH THE LITERATURE 
Summary of Finding My Study Finding Literature References 
    
1.     Smoking and risks of study outcomes         
Smoking increases the risks of 
LBW and SGA  
Smoking increases the risks of 
LBW and SGA 
Silverman 1977 
2.     Chronic diseases and risks of study 
           Outcomes 
Diabetes, hypertension increase 
risks of LBW, SGA and PTB 
Diabetes, hypertension increase 
risks for LBW, SGA and PTB 
Casson 1997 
3.      Prevalence of AD among different 
            Ethnicities 
AD is more prevalent among BNH 
mothers 
AD is more prevalent among persons 
of African descent 
Williams 1999 
4.      Prevalence of AR among different 
            Ethnicities 
AR is more prevalent among WNH 
mothers 
AR is more prevalent among persons 
of European and Australian descent 
Hjern 2000 
5.     The proportion of women who 
           Smoke 
19.7% 12% - 22% CDC 2004 
6.     The proportion of women who  
           smoke while pregnant 
14.7% 18% – 25% quit while pregnant CDC 2004 
7.     Moms of VLBW infants has less atopy 
           compared to moms of full term 
           infants (rates not the same but 
           trends are) 
AR – 8.72% vs 11.00%, 
AD – 6.76% vs. 9.64% 
AR – 27% vs 34%, 
AD – 29% vs. 33% 
Savilahti 2004 
8.     Asthma increases risk of SGA and 
             PTB 
RR = 1.11 &1.20 resp. RR = 1.22 & 1.41 resp. Murphy 2011 
9.     Asthma increases risk of PTB RR = 1.20 RR = 1.15 Trønnes 2014 
10.   AR reduces the risk of PTB RR = 0.91  RR = 0.84  Trønnes 2014 
11.   AD reduces the risk of PTB RR = 0.98 RR = 0.90 Trønnes 2014 
12.   The prevalence of LBW in SC 10.1% 9.7% CDC 2015 
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APPENDIX B: FINDINGS WHICH DIFFER FROM THE LITERATURE 
Summary of Finding My Study Finding Literature References 
    
1.   Percentage of persons with NAA who 
           also have asthma 
15.5% 40% Pawankar 2002 
2.   Percentage of persons with asthma who 
           also have NAA 
10.1% 30% – 80%  Kim 2008 
3.   Asthma increases the risk of LBW in 
           WNH women not BNH women 
RR = 1.29 (WNH) 
RR = 0.96 (BNH) 
OR = 0.99 (WNH) 
OR = 1.70 (BNH) 
Aly 2011 
4.   The prevalence of atopy  7.20% 20% – 25% Franzese 2011 
5.   The prevalence of NAA 3.0% 20% – 30% Greiner 2012 
6.   The prevalence of asthma 4.6% 8% – 13% Murphy 2011 
7.   The prevalence of PTB in SC 9.5% 13.75% CDC 2015 
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APPENDIX C: FINDINGS RELATED TO LIMITATIONS (THIS STUDY WAS AGE RESTRICTED) 
Summary of finding My Study Finding Literature References 
    
1. The proportion of women 
with gestational diabetes 
3.3% 
9.2% among all pregnant 
women 
DeSisto 2010 
2. The proportion of women 
with diabetes 
0.7% 
1.5% among women 
under 44 years 
CDC 2015 
3. The proportion of women 
with hypertension 
2.0% 
6.8% among women 
aged 20 – 34 years 
CDC 2015 
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APPENDIX D: FINDINGS RELATED TO FUTURE DIRECTIONS (NO PREVIOUS 
DATA) 
Summary of Finding My Study Finding 
  
1. NAA reduces the risk of LBW & SGA among 
WNH women 
RR = 0.95 & 0.97 resp. 
2. NAA reduces the risk of LBW & SGA among 
BNH women 
RR = 0.94 & 0.84 resp. 
3. NAA does not affect the risk of PTB among 
BNH women 
RR = 1.0 
4. NAA with asthma is protective against LBW, 
SGA & PTB for BNH women 
RR = 0.79, 0.19, 0.85 resp. 
5. NAA with asthma increases the risk of LBW, 
SGA & PTB for WNH women 
RR = 1.40, 1.87, 1.11 resp. 
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APPENDIX E: DATA SELECTION 
 
Figure 13: Data Selection Step 1 
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Figure 14: Data Selection Step 2 
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APPENDIX F: ADDITIONAL STUDY TABLES 
 
 
Table 26: ICD Codes Used to Classify Patients as having a Non–Asthmatic Atopy 
ICD 9 Code Explanation AR/AD 
   
370.31 Phylctenular Keratoconjunctivitis  AD 
372.03 Mucopurulent Conjunctivitis – other AD 
372.05 Acute Atopic Conjunctivitis AD 
372.13 Vernal Conjunctivitis AD 
372.14 Chronic Allergic Conjunctivitis AD 
373.31 Eczematous Dermatitis – eyelid AD 
373.32 Contact and Allergic Dermatitis of the eyelid AD 
477.0 Allergic Rhinitis – pollen AR 
477.1 Allergic Rhinitis – food AR 
477.2 Allergic Rhinitis – animal hair/dander AR 
477.8 Allergic Rhinitis – other allergen AR 
477.9 Allergic Rhinitis – cause unspecified  AR 
691 Atopic Dermatitis AD 
691.8 Atopic Dermatitis AD 
692.84 Contact Dermatitis – animal hair/dander AD 
692.9 Contact Dermatitis – unspecified AD 
693.1 Dermatitis – food AD 
 
 
 
 
 
 
 
 
 
 
 99 
 
 
Table 27: Summary of Numeric Characteristics 
Characteristic Summary 
  
N 9965 
   
Mother’s age (years)  
 Range 19 – 25 
 Mean + SD 20.8 + 1.8 
   
Gestational age at birth (weeks)  
 Range 24 – 43 
 Mean + SD 38.6 + 2.0 
   
Birth weight (grams)  
 Range 140 – 6719 
 Mean + SD 3155.1 + 568.4 
   
Number of non – asthmatic disorders  
 Range 0 – 4 
 Median + IQR 0 + 0 
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Table 28: Maternal Demographic and Clinical Characteristics (N = 9965) 
Characteristic n (%) 
  
Mother’s age (years)  
 19 3,005 (30.2) 
 20 2,260 (22.7) 
 21 1,505 (15.1) 
 22 1,300 (13.1) 
 23 790 (7.9) 
 24 585 (5.9) 
 25 520 (5.2) 
   
Sex of infant  
 Female 4,825 (48.4) 
 Male 5,140 (51.6) 
   
Mother’s race  
 White non – Hispanic 4,607 (46.3) 
 Black non – Hispanic 4,556 (45.7) 
 Hispanic 698 (7.0) 
 Other 100 (1.0) 
   
Smoking prior to pregnancy 1,938 (19.5) 
   
Smoking during pregnancy 1,468 (14.7) 
   
Pre–pregnancy diabetes 70 ( 0.7) 
   
Gestational diabetes 329 (3.3) 
  
Pre–pregnancy hypertension 201 (2.0) 
  
Asthma 1,545 (15.5) 
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Table 29: Characteristics by Atopy Category 
Characteristic Non – Asthmatic Atopy Asthma 
 Present/Cases Absent/Controls Present Absent 
 (N = 1,993) (N = 7,972) (N = 1,545) (N = 8,420) 
     
Mother’s age (years)    
 Range 19 – 25 19 – 25 19 – 25 19 – 25 
 Mean + SD 20.8 + 1.8 20.8 + 1.8 20.9 + 1.8 20.8 + 1.8 
      
Gestational age at birth 
(weeks) 
  *** 
 Range 24 – 42 24 – 43 24 – 41 24 – 43 
 Mean + SD 38.6 + 2.0 38.6 +2.0 38.4 + 2.1 38.6 + 2.0 
      
Birth weight (grams)   *** 
 Range 420 – 5018 140 – 6719 775 – 6,332 140 – 6,719 
 Mean + SD 3170.7 + 560.8 3151.2 + 570.3 3,091.6 + 
580.0 
3,166.7 + 
565.5 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 30: Maternal Demographic and Clinical Characteristics by Atopy Category 
Characteristic Non–Asthmatic Atopy Asthma 
 Present/Cases  Absent/Controls Present Absent 
 (N = 1,993) (N = 7,972) (N = 1,545) (N = 8,420) 
      
Sex   *** 
 Female 48.4% 48.4% 52.4% 47.7% 
 Male 51.6% 51.6% 47.6% 52.3% 
Mother’s race *** *** 
 White non – Hispanic 48.2% 45.8% 44.3% 46.6% 
 Black non – Hispanic 48.0% 45.2% 51.5% 44.7% 
 Hispanic 3.3% 7.9% 3.6% 7.6% 
 Other 0.6% 1.1% 0.7% 1.1% 
Smoked prior to pregnancy ** *** 
 Yes 21.4% 19.0% 23.4% 18.8% 
Smoked during pregnancy   *** 
 Yes 15.2% 14.6% 18.8% 14.0% 
Pre–pregnancy diabetes present   ** 
 Yes 0.8% 0.7% 1.3% 0.6% 
Gestational diabetes present     
 Yes 3.4% 3.3% 3.2% 3.3% 
Pre–pregnancy hypertension present   ** 
 Yes 2.1% 2.0% 3.1% 1.8% 
Asthma present     
 Yes 15.5% 15.5% – – 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 31: Characteristics by NAA type 
Characteristic Allergic Rhinitisa Atopic Dermatitisa 
 Present Absent Present Absent 
 (N = 1,093) (N = 8,872) (N = 959) (N = 9,006) 
     
Mother’s age (years)   
 Mean + SD 20.9 + 1.8 20.8 + 1.8 20.8 + 1.7 20.8 + 1.8 
      
Gestational age at birth (weeks)    
 Mean + SD 38.5 + 2.0 38.6 +2.0 38.6 + 1.9 38.6 + 2.0 
      
Birth weight (grams)    
 Mean + SD 3176.2 + 563.3 3152.5 + 569.0 3161.3 + 561.6 3154.4 + 569.1 
aEach condition was considered separately 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
 
 
Table 32: Study Outcomes by Atopy Types and Combinations 
 
Outcome Asthma AR Present AR Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 1,545) (N = 8,420) (N = 232) (N = 861) (N = 1,313) (N = 7,559) 
       
LBWa 4.9% 4.3% 3.9% 4.6% 5.1% 4.2% 
       
SGAb 2.4% 2.0% 1.7% 2.4% 2.5% 1.9% 
       
PTB 11.5% 9.1% ** 12.5% 8.5% * 11.4% 9.2% ** 
aFor infants born after completing 37 weeks of gestation; N = 1,367 and 7,650 for Asthma present 
and absent respectively; N = 203 and 788 for Asthma present and absent respectively among 
mothers with AR; N = 1,164 and 6,862 for Asthma present and absent respectively among 
mothers without AR. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 33: Study Outcomes by Atopy Types and Combinations 
 
Outcome Asthma AD Present AD Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 1,545) (N = 8,420) (N = 100) (N = 859) (N = 1,445) (N = 7,561) 
       
LBWa 4.9% 4.3% 8.9% 4.0% * 4.6% 4.3% 
       
SGAb 2.4% 2.0% 3.0% 1.8% 2.4% 2.0% 
       
PTB 11.5% 9.1% ** 10.1% 9.3% 11.6% 9.1% ** 
aFor infants born after completing 37 weeks of gestation; N = 1,367 and 7,650 for Asthma present 
and absent respectively; N = 90 and 779 for Asthma present and absent respectively among 
mothers with AD; N = 1,277 and 6,871 for Asthma present and absent respectively among 
mothers without AD. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
 
Table 34: Summary of Numeric Characteristics by Maternal Race/Ethnicity 
Characteristic WNH BNH 
   
N 4,607 4,556 
    
Mother’s age (years) **   
 Range 19 – 25 19 – 25 
 Mean + SD 20.9 + 1.8 20.8 + 1.7 
    
Gestational age at birth (weeks) ***    
 Range 24 – 43 24 – 42 
 Mean + SD 38.7 + 1.9 38.4 + 2.2 
    
Birth weight (grams) ***    
 Range 506 – 5,018 140 – 6,719 
 Mean + SD 3,260.3 + 551.1 3,033.7 + 575.5 
    
No. of non – asthmatic disorders    
 Range 0 – 3 0 – 4 
 Median + IQR 0 + 0 0 + 0 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 35: Maternal Demographic and Clinical Characteristics by Maternal Race/Ethnicity 
Characteristic WNH 
(N = 4,607) 
BNH 
(N = 4,556) 
 n (%) n (%) 
   
Sex   
 Female 2,211 (48.0) 2,228 (48.9) 
 Male 2,396 (52.0) 2,328 (51.1) 
    
Smoking prior to pregnancy *** 1,478 (32.1) 398 (8.7) 
   
Smoking during pregnancy *** 1,152 (25.0) 274 (6.0) 
   
Pre–pregnancy diabetes ** 25 ( 0.5) 43 ( 0.9) 
   
Gestational diabetes * 137 (3.0) 166 (3.6) 
   
Pre–pregnancy hypertension *** 64 (1.4) 128 (2.8) 
   
Asthma ** 684 (14.9) 796 (17.5) 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 36: Summary of Characteristics by Atopy Category by Maternal Race/Ethnicity 
Characteristic WNH BNH 
 NAA Present NAA Absent NAA Present NAA Absent 
 (N = 960) (N = 3,647) (N = 957) (N = 3,599) 
     
Mother’s age (years)   
 Range 19 – 25 19 – 25 19 – 25 19 – 25 
 Mean + SD 20.9 + 1.8 20.9 + 1.8 20.8 + 1.8 20.8 + 1.7 
      
Gestational age at birth (weeks)      
 Range 24 – 42 24 – 43 24 – 42 24 – 42  
 Mean + SD 38.7 + 1.8 38.7 +1.9 38.4 + 2.1 38.4 +2.2  
       
Birth weight (grams)  *   
 Range 725 – 5,018 506 – 4,819 420 – 4,700 140 – 6,719  
 Mean + SD 3,288.2 + 537.1 3,252.9 + 554.5 3,053.5 + 563.1 3,028.5 + 578.7  
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 37: Maternal Demographic and Clinical Characteristics by NAA Category by Maternal 
Race/Ethnicity 
Characteristic WNH BNH 
 NAA Present  NAA Absent NAA Present NAA Absent 
 (N = 960) (N = 3,647) (N = 957) (N = 3,594) 
      
Sex     
 Female 48.3% 47.9% 48.3% 49.1% 
 Male 51.7% 52.1% 51.7% 50.9% 
      
Smoking prior to pregnancy 33.2% 31.8% 9.6% 8.5% 
      
Smoking during pregnancy 24.3% 25.2% 6.3% 6.0% 
      
Pre–pregnancy diabetes 0.8% 0.5% 0.7% 1.0% 
      
Gestational diabetes 3.0% 3.0% 3.8% 3.6% 
     
Pre–pregnancy hypertension 2.0% 1.2% * 2.3% 3.0% 
     
Asthma 13.2% 15.3% 17.4% 17.5% 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 38: Study Outcomes by Atopy Types and Combinations among WNH women 
 
Outcome Asthma AR Present AR Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 684) (N = 3,923) (N = 101) (N = 471) (N = 583) (N = 3,452) 
       
LBWa 3.9% 2.8%  4.4% 2.5% 3.8% 2.8%  
       
SGAb 2.3% 1.5% *  3.0% 1.3% 2.2% 1.5% 
       
PTB 10.1% 8.1% * 9.9% 7.6% 10.1% 8.2% 
aFor infants born after completing 37 weeks of gestation; N = 615 and 3,605 for Asthma present 
and absent respectively; N = 91 and 435 for Asthma present and absent respectively among 
mothers with AR; N = 524 and 3,170 for Asthma present and absent respectively among mothers 
without AR. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
Table 39: Study Outcomes by Atopy Types and Combinations among BNH women 
Outcome Asthma AR Present AR Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 796) (N = 3,759) (N = 120) (N = 369) (N = 676) (N = 3,390) 
       
LBWa 5.9% 6.0% 2.9% 6.9% 6.4% 5.9% 
       
SGAb 2.5% 2.5% 0.8% 3.5% 2.8% 2.4% 
       
PTB 13.0% 11.0% 15.0% 10.1% 12.6% 11.1% 
aFor infants born after completing 37 weeks of gestation; N = 693 and 3,348 for Asthma present 
and absent respectively; N = 102 and 332 for Asthma present and absent respectively among 
mothers with AR; N = 591 and 3,016 for Asthma present and absent respectively among mothers 
without AR. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 40: Study Outcomes by Atopy Types and Combinations among WNH women 
Outcome Asthma AD Present AD Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 684) (N = 3,923) (N = 33) (N = 374) (N = 651) (N = 3,549) 
       
LBWa 3.9% 2.8%  10.0% 2.6% * 3.6% 2.8%  
       
SGAb 2.3% 1.5% *  9.1% 1.3% ** 2.0% 1.5% 
       
PTB 10.1% 8.1% * 9.1% 7.0% 10.1% 8.2% * 
aFor infants born after completing 37 weeks of gestation; N = 615 and 3,605 for Asthma present 
and absent respectively; N = 30 and 348 for Asthma present and absent respectively among 
mothers with AD; N = 585 and 3,257 for Asthma present and absent respectively among mothers 
without AD. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
 
 
 
 
Table 41: Study Outcomes by Atopy Types and Combinations among BNH women 
Outcome Asthma AD Present AD Absent 
 Present Absent Asthma No Asthma Asthma No Asthma 
 (N = 796) (N = 3,759) (N = 61) (N = 446) (N = 735) (N = 3,313) 
       
LBWa 5.9% 6.0% 9.1% 5.3% 5.6% 6.1% 
       
SGAb 2.5% 2.5% 0.0% 2.0% 2.7% 2.6% 
       
PTB 13.0% 11.0% 10.0% 11.7% 13.2% 10.9% * 
aFor infants born after completing 37 weeks of gestation; N = 693 and 3,348 for Asthma present 
and absent respectively; N = 55 and 394 for Asthma present and absent respectively among 
mothers with AD; N = 638 and 2,954 for Asthma present and absent respectively among mothers 
without AD. 
bBirth weight less than 2 standard deviations from the sex– and gestational age–specific mean 
*p < 0.10; **p < 0.05; ***p < 0.001  
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Table 42: Summary of Numeric Characteristics for Selected Controls to Remaining Controls 
Characteristic SC RC 
   
N 7,972 55,678 
    
Mother’s age (years) ***   
 Range 19 – 25 19 – 25 
 Mean + SD 20.8 + 1.8 21.2 + 1.8 
    
Gestational age at birth (weeks)    
 Range 24 – 43 24 – 45 
 Mean + SD 38.6 + 2.0 38.6 + 2.0 
    
Birth weight (grams) *    
 Range 140 – 6,719 324 – 6,269 
 Mean + SD 3,151.2 + 570.3 3,164.5 + 568.4 
*p < 0.10; **p < 0.05; ***p < 0.001  
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APPENDIX G: ADDITIONAL STUDY FIGURES 
 
 
 
Figure 15: Percent of Mothers with Allergic Rhinitis by Infant Birth Weight 
p < 0.001 for increasing trend 
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Figure 16: Percent of Mothers with Atopic Dermatitis by Infant Birth Weight 
p < 0.001 for increasing trend 
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Figure 17: Percent of Mothers with Allergic Rhinitis by Infant Gestational Age at Birth 
p < 0.001 for increasing trend  
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Figure 18: Percent of Mothers with Allergic Rhinitis by Fetuses at Risk for Gestational Age at 
Birth 
p < 0.001 for overall increasing trend 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks 
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Figure 19: Percent of Mothers with Atopic Dermatitis by Infant Gestational Age at Birth 
p < 0.001 for increasing trend 
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Figure 20: Percent of Mothers with Atopic Dermatitis by Fetuses at Risk for Gestational Age at 
Birth 
p < 0.001 for overall increasing trend 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks 
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Figure 21: Percent of Mother with Allergic Rhinitis by Infant Birth Weight by Race/Ethnicity 
p < 0.001 for increasing trend among WNH mothers 
p < 0.001 for increasing trend among BNH mothers 
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Figure 22: Percent of Mothers with Atopic Dermatitis by Infant Birth Weight by Race/Ethnicity 
p < 0.001 for increasing trend among WNH mothers 
p < 0.001 for increasing trend among BNH mothers 
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Figure 23: Percent of Mothers with Allergic Rhinitis by Infant Gestational Age at Birth by 
Race/Ethnicity 
p < 0.001 for increasing trend among WNH mothers 
p < 0.001 for increasing trend among BNH mothers 
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Figure 24: Percent of Mothers with Allergic Rhinitis by Fetuses at Risk for Gestational Age at 
Birth by Race/Ethnicity 
p < 0.001 for overall increasing trend among WNH mothers 
p < 0.001 for overall increasing trend among BNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers 
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Figure 25: Percent of Mothers with Atopic Dermatitis by Infant Gestational Age at Birth by 
Race/Ethnicity 
p < 0.001 for increasing trend among WNH mothers 
p < 0.001 for decreasing trend among BNH mothers 
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Figure 26: Percent of Mothers with Atopic Dermatitis by Fetuses at Risk for Gestational Age at 
Birth by Race/Ethnicity 
p < 0.001 for overall increasing trend among WNH mothers 
p < 0.001 for overall increasing trend among BNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among WNH mothers 
p < 0.001 for increasing trend for gestational age at birth < 36 weeks among BNH mothers 
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APPENDIX H: HISTORY OF MEDICAID IN SOUTH CAROLINA 
 
HISTORY OF MEDICAID 
In 1965 Medicaid was created by an addition made to The Social Security Act. Under 
Title XIX, 42 U.S.C. §§ 1396 et seq, the federal government provides funds to states to enable 
them to provide medical assistance to residents who meet certain eligibility requirements. The 
program was created in order to assist states in providing health care to residents who lack the 
income and resources to access necessary medical care. Medicaid serves as the nation’s primary 
source of health insurance coverage for low–income populations. 
 
 
SOUTH CAROLINA 
As a condition for receipt of Federal funds under Title XIX of the Social Security Act, the 
42 CFR 430.10 Department of Health and Human Services; a Single State Agency, is responsible 
for the state’s plan for the medical assistance program. It also administers the program in 
accordance with the provisions of the State Plan, the requirements of title XI and XIX of the Act, 
and all applicable Federal regulations and other official issuances of the Department (July 1, 1995). 
 
 
 
 
 124 
 
 
APPENDIX I: LIST OF ABBREVIATIONS AND TERMS USED IN THIS DISSERTATION 
 
ABBREVIATIONS 
NAA – Non – Asthmatic Atopy 
AR – Allergic Rhinitis 
AD – Atopic Dermatitis 
LBW – Low Birth Weight 
VLBW – Very Low Birth Weight 
ELBW – Extremely Low Birth Weight 
PTB – Preterm Birth 
SGA – Small for Gestational Age 
LGA – Large for Gestational Age 
ICS – Inhaled Corticosteroid 
ETS – Environmental Tobacco Smoke 
SC – Selected Controls 
RC – Remaining Controls 
ASD – Autism Spectrum Disorders 
CA – Congenital Abnormality 
WNH – White non – Hispanic 
BNH – Black non–Hispanic 
SD – Standard Deviation 
 125 
 
IQR – Interquartile Range 
OTC – Over the counter 
RRC – Crude relative risk 
RRA – Adjusted relative risk 
 
TERMS 
Risk factor – Increases the risk of an outcome 
Protective factor – Reduces the risk of an outcome 
Tend toward significance – p < 0.10 
Mildly significant – p < 0.10 
Significant – p < 0.05 
Not significant – p > 0.10 
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APPENDIX J: IRB APPROVAL LETTER 
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APPENDIX K:  AUTHORIZATION TO USE MEDICAID DATA 
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